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Abstract  
 
Systemic Lupus Erythematosus (SLE) is a multi-organ autoimmune disease 
characterised by the breakdown of immune tolerance, and a defect in the 
clearance of apoptotic material. There is an unmet need for better biomarkers 
to diagnose and monitoring of SLE. Type I interferon (IFN-I) has a crucial role 
in pathogenesis of SLE and IFN-I varies between patients. IFN-I has previously 
been measured using a signature of IFN-I-inducible genes but these have not 
been applied in routine clinical practice due to lack of validated assays and 
clinical validation. Tetherin (CD317) is an interferon-inducible protein expressed 
on the cell surface, and therefore, amenable to measurement using flow 
cytometry. Measurement of tetherin in specific cell subsets appeared to be a 
useful biomarker in SLE in discovery studies. 
In this study tetherin protein expression was assessed on whole blood and 
peripheral blood mononuclear cells using flow cytometry. It was determined that 
a whole blood assay reporting median tetherin MFI was convenient and 
applicable in a routine diagnostic laboratory. IFN-I inducible gene expression 
was measured by quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) for comparison with tetherin. Healthy control (n=20), SLE-remission 
(n=66) and SLE-flare (n=65) groups were recruited from Leeds Lupus Clinic and 
tetherin levels were compared. Tetherin was increased in SLE patients with 
sensitivity (65.56%) and specificity (70%), with similar findings for gene 
expression. Tetherin expression on memory B cells, but not monocytes, 
predicted flare in patients in remission. However, repeat measurement of 
tetherin at follow up in flare patients (n=15) did not significantly reduce. The 
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potential use of tetherin and IFN-I inducible gene expression to stratify patients 
to appropriate biologics was explored. 
These results demonstrate the potential value of tetherin as a biomarker in a 
routine clinical practice setting. Results have been used to design definitive 
validation studies. 
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1.0 Introduction  
 
Overview 
 
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease with 
heterogeneous clinical manifestations and immunopathogenesis (Tsokos, 
2011, Sieber et al., 2014). It is a chronic inflammatory disease that is 
characterised by the dysfunction of T lymphocytes, dendritic cells, B cells and  
by the production of antinuclear autoantibodies (Perl, 2010). SLE is also 
associated with abnormally raised cytokine levels, including interleukin 6 (IL-6), 
B-cell activating factor (BAFF), and most notable, type I interferon (IFN). These 
atypical levels are thought to have fundamental roles in the maintenance and 
progression of the disease (Grondal et al., 2000, Munroe et al., 2014). The exact 
aetiology of SLE is unclear, however,  initiation of the disease appears to 
depend on a combination of genetic susceptibility, immunological and 
environmental factors (Figure 1) that predispose and/or contribute to 
pathogenic autoimmunity (Grammer and Lipsky, 2003).  
More than 90% of cases of SLE are diagnosed in women of childbearing age. 
The incidence rates in Europe vary; however, they are usually between 2 to 4.7 
per 100,000 population per year and prevalence range from 20 to 150 cases 
per 100,000 in the overall population. The prevalence of SLE in the UK is 
approximately 25-30 per 100 000 adults (Haque et al., 2008). The concordance 
of SLE in monozygotic twins is approximately 25–50% and in dizygotic twins is 
around 2-5% (Harley et al., 2009). Aforementioned suggests that genetic factors 
play an influential role in predisposition to the disease. However, most cases of 
SLE are sporadic, indicating that multiple environmental or unknown factors 
may influence occurrence (Mok and Lau, 2003).  
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 The disease’s clinical manifestations range from mild symptoms such as skin 
rash, fever, joint pain, fatigue and arthralgia to severe forms of the disease 
affecting the kidneys, heart and central nervous system (CNS) (Rahman and 
Isenberg, 2008). However, the gastrointestinal tract is the most commonly 
affected system in SLE patients, with its manifestations similar to that of viral 
infections. The disease show highest prevalence and can be most aggressive 
in the African-American and African-Caribbean populations, however, SLE also 
affects Asian and Caucasian populations (Danchenko et al., 2006).  
Genetic susceptibility includes genes that are involved in multiple functions such 
as; activation, proliferation, differentiation, survival of immunoglobulin secreting 
cells (ISCs). Additionally, the pathogenesis of SLE includes genes involved in 
the presentation and clearance of apoptotic materials and autoantigens by 
antigen presenting cells and other phagocytes (Mok and Lau, 2003). It has been 
shown that the progressive loss of tolerance to nuclear antigens over time, 
impaired clearance of immune complexes (ICs) and apoptotic materials, and 
the production of autoantibodies results in clinical disease (Elkon and Stone, 
2011). Also there has been a strong correlation between elevated IFNs and SLE 
disease activity (Banchereau and Pascual, 2006, Landolt-Marticorena et al., 
2009). Type I IFN has been shown to be one of the most important factors in 
the pathogenesis of SLE. This is because genes in the IFN pathway and 
regulation of innate immune responses have been identified in SLE 
susceptibility such as interferon regulatory factor 5 (IRF5) and signal transducer 
and activator of transcription 4 (STAT4).  The heterogeneity of clinical features 
and the disease’s unpredictable course can be characterised by flares and 
remissions (Obermoser and Pascual, 2010). 
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Over the past decade the type I IFN cytokine family has been suggested to play 
a central role in SLE pathogenesis (Obermoser and Pascual, 2010), by 
promoting feedback loops that progressively disrupt peripheral immune 
tolerance, which drives disease activity. The identification of novel molecules 
involved in the pathogenesis of SLE will improve understanding of the 
complexity of the disease, and may also help to identify novel targets for 
biological intervention (Obermoser and Pascual, 2010). Tetherin, an alpha 
interferon-inducible cellular factor, is a possible key molecule that could play a 
role in predicting flare or disease activity in SLE patients, and is therefore the 
target molecule in this study.     
 
Figure 1: Factors that trigger the development of SLE 
 
Genetic-susceptibility factors, environmental factors, antigen-antibody (Ab) responses, B-cell 
and T-cell interactions, and immune clearance processes interact to generate and perpetuate 
autoimmunity. HLA = human leukocyte antigen; UV = ultraviolet light. 
http://emedicine.medscape.com/article/332244-overview#a4.  
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1.1 The role of interferon (IFN) in pathogenesis of SLE 
 
IFNs are signalling proteins (De Andrea et al., 2002) and they were first 
recognised for their ability to impede viral replication (Vilcek, 2006). However, 
the antiviral potency of individual IFN varies considerably, and they modulate 
functions of the immune system.  There are three types of IFNs, and they are 
categorised based upon the amino acid sequence and recognition of specific 
receptors (Theofilopoulos et al., 2005). Type I IFN comprises; IFN-α, IFN-β, 
IFN-ε, IFN-κ and IFN-ω (van Boxel-Dezaire et al., 2006, Noppert et al., 2007). 
Whereas, Type II IFN consists of a single member, IFN-γ and Type III IFN (IFN-
λ1-4)  (Obermoser and Pascual, 2010). 
 
IFN-α is produced in virally infected leukocytes while IFN-β is from virally 
infected fibroblasts and keratinocytes. IFN-γ is induced by the stimulation of 
sensitised lymphocytes with antigen or non-sensitised lymphocytes with 
mitogens (Imanishi, 1994). IFNs do not only have antiviral activity but also 
various kinds of biological activities including cell growth inhibition, 
immunosuppressive effects, natural killer (NK) cells, killer (K) cells and 
neutrophil functions, enhancement of macrophage activity and cell 
differentiation-inducing activity (Imanishi, 1994). IFNs are also involved in the 
pathogenesis of various diseases, including, such as SLE, rheumatoid arthritis, 
insulin-dependent diabetes mellitus, severe pancreatitis, nephritis, multiple 
sclerosis, and atherosclerosis. IFNs are clinically used in therapy against viral 
infections such as hepatitis B and C (Parkin and Cohen, 2001), and for 
malignancies, such as skin cancers, renal cell carcinoma, and chronic 
myelogenous leukaemia (Imanishi, 1994). 
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IFN activity was first discovered in the serum of patients suffering from several 
autoimmune diseases in 1979 (Hooks et al., 1979, de Weerd et al., 2007), a 
finding which was later confirmed mainly in SLE patients (Preble et al., 1982, 
Kirou et al., 2005). The role of type I IFN-α and IFN-β in SLE was observed from 
the induction of autoimmunity during IFN-α/β infusion (Ronnblom et al., 1991) 
and the increased levels presence of IFN-α/β in SLE patients’ blood. This 
confirmed that IFNs levels directly correlated with SLE disease activity (Blanco 
et al., 2001).  
 
 
1.2 Mechanisms associated with the pathogenesis of SLE. 
 
Multiple immune abnormalities contribute to the pathogenesis of SLE. These 
include abnormal clearance of apoptotic cells, immune complexes (ICs) and low 
thresholds of activation of B and T cells which leads to loss of self-tolerance 
and autoantibody production (Elkon and Stone, 2011). It has been shown that 
these autoantibodies are directed against nucleic acids (DNA) and associated 
nuclear proteins as well as ribonuclear proteins (RNP) such as Ro, La, and Sm 
(Tan, 1989).  
Both environmental and genetic risk factors are critical in the development of 
SLE. The disease is nine folds higher in females than in males; indicating that 
hormones make a major contribution in the development of SLE. Human 
leukocyte antigen (HLA) associations HLA-B8 and HLA-DR3 and complement 
deficiencies, especially of early complement components C1q, C2, and C4 are 
associated with an increased risk of SLE (Truedsson et al., 2007). It has been 
suggested that more than 90% of individuals who have a homozygous 
deficiency of C1q develop SLE with more severe disease manifestations 
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(Pickering and Walport, 2000). C1q deficiency inhibits the clearance of 
apoptotic cells and can also upregulate cytokine production by other immune 
cells (Fraser et al., 2009). 
 
Kirou et al (2005) reported that low complement levels are associated with the 
activation of the type I IFN pathway, which could explain the increased disease 
activity (Kirou et al., 2005). Studies performed by Lood et al and Santer et al 
showed that C1q plays a direct role in the regulation of IFN-α stimulation by 
SLE ICs (Lood et al., 2009, Santer et al., 2010). There has been evidence of 
three monogenic deficiencies of C1q, three prime repair exonuclease 1 
(TREX1), and tartrate-resistant acid phosphatase (TRAP) have been identified 
to show in clinical phenotypes consistent with lupus (Elkon and Stone, 2011). 
TREX1 mutations were found in up to 2.7% of SLE patients (Lee-Kirsch et al., 
2007, Namjou et al., 2011). In an analysis of over 8,000 multi-ancestral lupus 
patients two discoveries were made (Namjou et al., 2011), 1) a TREX1 risk 
allele was linked with neurologic manifestations, especially seizure in patients 
of European descent. 2), a strong association between a TREX1 single-
nucleotide polymorphism and anti-nRNP antibodies was seen (Namjou et al., 
2011).  
There are more than 100 genetic variants (only eight consistently replicated) 
that confer the increased risk of SLE susceptibility. However, only a small effect 
has been identified by genome-wide association studies (GWAS) (Harley et al., 
2009). The three monogenic syndromes and multiple genetic variants identified 
by GWAS are involved in the type I IFN pathway, which further highlight the 
significance of this pathway in SLE (Deng and Tsao, 2010, Sestak et al., 2011). 
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1.2.2 Diagnosis of SLE 
 
There are numerous diagnostic tests available to aid the diagnosis of SLE; 
however, no laboratory assay has 100 percent (100%) accuracy and precision, 
and clinical tests are often compromised by subjectivity. SLE patients are 
primarily women who present with chronic nonspecific symptoms such as 
weight loss, fever and fatigue (Banchereau and Pascual, 2006). The American 
College of Rheumatology (ACR) criteria for the diagnosis of SLE includes 
detection of several autoantibodies (Table 1). Confirming the diagnosis of SLE 
requires the fulfilment of four out of the eleven clinical and immunological criteria 
to be present at some time-point. One of those includes the presence of anti-
nuclear antibodies (ANAs); ANAs are detected in >95% of SLE patients 
(Banchereau and Pascual, 2006). Antiphospholipid antibodies (APLs) are 
detected in approximately 60% of patients with SLE and Anti-Sm protein is 
found in approximately 30% of people with lupus. A positive test supports a 
lupus clinical diagnosis; however, relying on these antibody results alone could 
lead to a false positive or false negative diagnosis.  
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Classification and Clinical Features of SLE by ACR Criteria 
Criteria Definition 
Malar Rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds 
Discoid Rash  Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring occurs in older lesions 
Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history 
or physician observation 
Oral Ulcers Oral or nasopharyngeal ulceration, usually painless, observed by a 
physician 
Arthritis Non-erosive arthritis involving two or more peripheral joints, 
characterised by tenderness, swelling or effusion 
Serositis a) Pleuritis: convincing history of pleuritic pain or rub heard by a 
physician or evidence of pleural effusion or 
b) Pericarditis: documented by ECG or rub or evidence of pericardial 
effusion 
Renal Disorder a) Persistent proteinuria >0.5 g per day or >3+ if quantitation is not 
performed or  
b) Cellular casts: may be red cell, haemoglobin, granular tubular, or 
mixed. 
Neurological 
Disorder 
a) Seizures: in the absence of off ending drugs or known metabolic 
derangements (e.g., uraemia, acidosis, or electrolyte imbalance) or  
b) Psychosis: in the absence of off ending drugs or known metabolic 
derangements (e.g., uraemia, acidosis, or electrolyte imbalance) 
Haematological 
Disorder 
a) Haemolytic anaemia with reticulocytosis, or 
b) Leucopoenia: <4000/mm3, or 
c) Lymphopenia: <1500/mm3, or 
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Criteria Definition 
d) Thrombocytopenia: <100,00mm3, in the absence of off ending 
drugs 
Immunological 
Disorder 
a) Anti-DNA: antibody to native DNA in abnormal titre, or 
b) Anti-Sm: presence of antibody to Sm nuclear antigen, or 
 c) Positive finding of antiphospholipid antibodies based on: (1) an 
abnormal serum concentration of IgG or IgM anticardiolipin 
antibodies, (2) a positive test result for lupus anticoagulant using a 
standard method, or (3) a false positive serologic test for syphilis 
known to be positive for at least 6 months and confirmed by 
Treponema pallidum immobilisation or fluorescent treponemal 
antibody absorption test. 
Antinuclear 
Antibody 
 
An abnormal titre of antinuclear antibody by immunofluorescence or 
an equivalent assay at any point in time and in the absence of drugs 
known to be associated with ‘drug-induced lupus’ syndrome. 
Table 1: The American College of Rheumatology revised classification criteria 
for SLE. 
The classification of SLE is based on the presence of at least 4 of 11 criteria 
according to the American College of Rheumatology revised in 1997 (Hochberg, 
1997). The criteria present high sensitivity (>85%) and specificity (>95%) and 
include both clinical and serological parameters. 
 
Due to the positive contribution of serology in SLE, the criteria were revised in 
2012 by the Systemic Lupus International Collaborating Clinics (SLICC). As it 
is now at least one clinical and one laboratory criteria in the total 4 are required 
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for the diagnosis of SLE (Table 2) (Petri et al., 2012). However, the criteria were 
validated for SLE patients with longstanding disease history. 
Clinical Criteria Immunologic Criteria 
Acute Cutaneous Lupus ANA 
Chronic Cutaneous Lupus Anti-DNA 
Oral or Nasal Ulcers Anti-Smith (anti-Sm) 
Non-scaring Alopecia Antiphospholipid Ab 
Arthritis Low Complement (C3, C4, CH50)  
Serositis Direct Coombs’ Test 
Renal   
Neurologic   
Haemolytic Anaemia   
Leukopenia   
Thrombocytopenia 
(<100,000/mm3) 
 
Table 2: The SLICC classification criteria for SLE 
 
There are several laboratory techniques used to detect antinuclear antibodies 
(ANA) such as: Immunodiffusion (ID), which detects high affinity antibodies, 
immunofluorescence (IIF), which detects moderate and high affinity antibodies, 
and finally, enzyme linked immunosorbent assay (ELISA) which can identify low 
and high affinity antibodies. The most common techniques used in the UK are 
dsDNA ELISA, Crithidia luciliae IIF (CLIIF), or Farr immunoprecipitation assays 
(Egner, 2000). 
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Farr assays have been shown to be specific, but also detect high affinity IgM 
anti-dsDNA. IgG specific ELISA or CLIIF methods may produce similar results 
to Farr assays. It is believed that local validation of each assay is essential to 
ensure adequate diagnostic performance (Egner, 2000). There are limitations 
of these tests; for example, purified antigens maybe contaminated, or may not 
contain the full complement of native proteins. Recombinant antigens might lack 
certain epitopes, or contain contaminating bacterial antigens. All assays require 
careful validation to determine whether they perform adequately for detecting 
human autoantibodies (Egner, 2000). There is a need to develop specific 
assays for diagnosis of SLE, and there are on-going experiments for the 
development of biomarkers and more accurate assays. The use of serology 
tests to diagnose SLE is that they are not specific. For instance, ANA is present 
in individuals that do not have SLE. Currently there is the use to anti-dsDNA 
titres, erythrocyte sedimentation rate (ESR), complement levels and 
immunoglobulin titres to predict flare which are not reliable and specific. Hence 
why the discovering of a reliable and specific biomarker to predict flare will be 
beneficial to the patients and it will save cost for the National Health Service 
(NHS).   
 
1.2.3 Treatment of SLE 
 
Treatment of SLE depends on disease severity and disease manifestations 
(Hahn, 2005). Hydroxychloroquine has a central role for long-term treatment in 
all SLE patients. The Lupus in Minorities: Nature versus Nurture (LUMINA) 
study (2007 with 608 patients) and other trials have offered evidence of a 
decrease in flares and prolonged life in patients given hydroxychloroquine, 
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making it the basis of SLE management (Alarcon et al., 2007). Anti-malarials 
such as hydroxychloroquine, cyclophosphamide, methotrexate and 
mycophenolate mofetil (MMF) are widely used for the treatment of mild 
manifestations of SLE.  For SLE patients without major organ manifestations, 
glucocorticoids and antimalarial agents are usually given (Bertsias et al., 2008). 
Glucocorticoids are the backbone of therapy in the acute phase. Furthermore, 
immunosuppressive or immunomodulatory drugs alone or in combination can 
be used for the control or reduction of disease activity in the long-term.  
 
Biologic therapies have recently been added to the SLE therapeutic 
armamentarium such as belimumab and rituximab. These drugs act by 
inhibiting the number of circulating B cells function. B-cell depletion can be 
achieved by targeting the cell surface marker CD20 (rituximab (RTX)). RTX is 
a common treatment option, particularly in the case of more severe disease. 
There is clinical improvement in patients treated with the B cell-depleting CD20 
antibody compared to those taking hydroxychloroquine (Vital et al., 2012, Md 
Yusof et al., 2017). 
  
The field of biological therapies has encountered many setbacks regarding SLE 
treatment. However, belimumab, monoclonal antibody against B-lymphocyte 
stimulator (BLyS) stands out, with two phase 3 trials (BLISS-52 and BLISS-76) 
that met the primary outcome, the SLE responder index (Lateef and Petri, 
2010). Belimumab is licensed for add-on therapy in adults with active, 
autoantibody-positive SLE with a high degree of disease activity. In the United 
Kingdom (UK) belimumab is commissioned only if: the SLE Disease Activity 
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Index (SLEDAI) score is ≥10 at baseline, anti-double stranded deoxyribonucleic 
acid (dsDNA) antibodies titers are raised and complement levels (C3 and C4) 
are low. This is because these criteria predicted a higher response rate in 
clinical trials. SLEDAI and British Isles Lupus Activity Group (BILAG) are 
validated scales of disease activity. 
 
 A phase 1 dose-escalation study (Yao et al., 2009) evaluated the effects of a 
single dose of anti-IFN monoclonal antibody therapy in SLE. Anifrolumab is an 
antagonist human monoclonal antibody (IgG1 κ) that targets interferon α 
receptor 1 (IFNAR1) and prevents signalling by all type I IFNs. Anifrolumab has 
been established to treat autoimmune diseases (Peng et al., 2015) and has 
been assessed in a phase IIb, randomized, double-blind, placebo-controlled 
study of adult patients with moderate to severe SLE (Merrill, 2016). It has 
proven to substantially reduced disease activity compared with placebo across 
multiple clinical endpoints. It is currently in pivotal phase III studies. 
Despite the therapeutic advances, side effects affect many patients. Potential 
side effects are gastrointestinal disturbance, increased risk of infection, liver 
toxicity, decreased fertility and an increased risk of cancer as well as long-term 
glucocorticoid toxicity. Many patients fail to respond to existing treatment. 
Cardiovascular toxicity is markedly increased. It is thought that long-term 
outcomes would be improved if patients could maintain in a state of low disease 
activity (i.e. without flare). For this reason, predictors of flare would be valuable 
to (i) give pre-emptive therapy if a flare is imminent to prevent the flare; and (ii) 
reduce potentially toxic therapy in patients whose risk of flare is low. 
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1.3 The role of B cells in SLE 
 
B-cells play a key role in the pathogenesis of SLE by secreting autoantibodies. 
The presence of autoantibodies in SLE patients is a defining characteristic of 
the disease, with many of these making a major contribution to disease 
pathogenesis, for example anti-DNA antibodies. B-cells also act as antigen 
presenting cells, activating T-cells.  Finally, they secrete both pro-inflammatory 
and anti-inflammatory cytokines (Nashi et al., 2010, Sieber et al., 2014); such 
as IL-4, IL-6, IL-10, IFN-γ, Transforming Growth Factor-β and Lymphotoxin-α 
(Anolik, 2007). 
 
1.4 Lymphocytes as antigen-presenting cells in SLE 
 
Several studies have demonstrated that B-cells are active participants in 
humoral immune responses that lead to differentiation of ISCs (Grammer and 
Lipsky, 2003). Furthermore, differentiation of ISCs has been shown to be 
affected by stimulation from B-cell activating factor (BAFF/BlyS/TNFSF13B). 
BAFF is coded for in an SLE susceptibility locus (13q32-34) (Blomberg et al., 
2001, Honda et al., 2005) and has been shown to be higher in the serum of 
patients with active SLE (Jahnsen et al., 2000, Le Bon et al., 2001).  
Studies have revealed that B-cells play a role in auto-regulating humoral 
immune responses, and data suggested that B cells from active SLE patients 
have an intrinsic tendency to overreact to immunologic stimulation during 
antigenic challenge (Grammer and Lipsky, 2003). This sets the stage for novel 
hypotheses regarding therapeutic approaches to interfere with the development 
and progression of SLE (Grammer and Lipsky, 2003). The B-cell abnormalities 
observed in SLE patients may either reflect the impact of multiple genetic 
  
Page 30 
 
  
factors that affect intrinsic B cell function and/or they may be secondary to other 
primary immunologic abnormalities (Shlomchik et al., 2001). Evidence has 
suggested there is alteration of a tolerance checkpoint in SLE patients (Yurasov 
et al., 2005). It has been shown that altered B-cell tolerance checkpoints in SLE 
comes from B cells expressing the VH4-34 gene, that encodes autoantibodies 
of different specificities (Banchereau and Pascual, 2006). Data has shown that 
in healthy individuals, VH4-34+ B cells are excluded during the early stages of 
the germinal centre (GC) reaction, therefore representing a second tolerance 
checkpoint in the life of a B cell. Whereas, in SLE patients, VH4-34+ B cells 
progress through this checkpoint, participate in GC reactions, and also 
expanded within the post-GC IgG memory and plasma cell compartments 
(Cappione et al., 2005). 
 
1.5 Autoantibodies  
 
Anti-DNA antibodies are extensively studied in lupus. It has been shown that in 
SLE patients 50-70% of these antibodies are present at some stage in the 
disease (Nashi et al., 2010) and their presence supports diagnosis of the 
disease. A number of studies have shown that titres of anti-DNA antibodies tend 
to rise during flares of SLE disease activity particularly in lupus nephritis. 
Despite these findings, it is important to remember not all anti-DNA antibodies 
are pathogenic. Indeed, some anti-DNA antibodies have no pathogenic effect 
regardless of their DNA-binding affinities being equivalent to those of 
pathogenic antibodies (Nashi et al., 2010). It has been suggested that certain 
isotypes and antigen binding properties are associated with pathogenicity. IgG 
anti-double-stranded DNA (anti-dsDNA) antibodies for instance, are more 
  
Page 31 
 
  
clinically significant and are associated with increased disease activity and 
tissue damage compared with IgM antibodies (Isenberg et al., 1997), which 
have been shown to be protective (Witte, 2008). It was stated that anti-dsDNA 
antibodies have been shown to be more pathogenic than anti-single-stranded 
DNA antibodies. Anti-DNA antibodies from SLE patients with renal lupus exhibit 
a high affinity for DNA (Williams et al., 1999).  
 
Anti-nucleosome antibodies may be more important than anti-DNA antibodies 
in the aetiology of SLE. Nucleosomes, which consist of DNA wrapped around a 
core of histone proteins, are more important antigenic targets in lupus than 
naked DNA (Nashi et al., 2010). The levels of circulating nucleosomes have 
been shown to be increased in the plasma of lupus patients (Williams et al., 
2001). Furthermore, the levels of anti-nucleosome antibodies correlate strongly 
with lupus disease activity (Min et al., 2002), particularly with renal flare (Simon 
et al., 2004). The study by Ng et al (2006) showed that patients with higher titres 
of anti-nucleosome antibodies have a shorter time to flare after a serologically 
active but clinically quiescent period (Ng et al., 2006). These studies propose 
that titres of anti-nucleosome antibodies could be a better tool and have greater 
clinical significance than titres of anti-DNA antibodies in predicting flare (Nashi 
et al., 2010). 
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1.6 The role of T-cells in SLE 
 
Studies in patients with SLE have established that autoantigen-reactive T-cells 
can be isolated from peripheral blood and these cells can support autoantibody 
production ex vivo (Hoffman, 2004). This suggests that they have a central role 
in the pathogenesis of the disease. Previous work has identified and 
characterised signalling abnormalities in T-cells from SLE patients that may be 
fundamental to the disease (Hoffman, 2004). T-cells contribute to the initiation 
and development of autoimmunity in SLE and seem to be involved in the 
development of related organ damage (Crispin et al., 2010). The cytokine 
expression pattern is characterised by decreased expression of interleukin-2 
(IL-2) and increased production of IL-17 and related cytokines (Crispin et al., 
2010). Biochemical description of SLE T-cells has revealed distinct early and 
late signalling abnormalities, and has enabled the identification of novel 
molecular targets that can be corrected with small molecules, and biomarkers 
that may predict disease activity and organ damage (Crispin et al., 2010).  
Abnormal T-lymphocyte activation and cell death signalling underlie the 
pathology of SLE (Kyttaris et al., 2005). Mitochondria, which control death signal 
processing, are dysfunctional in lupus T-cells (Perl et al., 2009). This is believed 
to manifest as a persistent elevation of the mitochondrial trans-membrane 
potential or mitochondrial hyperpolarisation (MHP) (Gergely et al., 2002). 
Whereas, adenosine triphosphate (ATP) depletion, which predisposes the cell 
to death by necrosis. The increased release of necrotic materials from T-cells 
may drive disease pathogenesis by activating macrophages and dendritic cells 
(DCs) and enhancing their capacity to produce nitric oxide and IFN-α in SLE 
(Perl et al., 2004). 
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 Preliminary observations by Banchereau and Pascual (2006) suggest that IFN-
α/β stimulated DCs might favour the generation of these pathogenic cells. IFN-
α was shown to strongly enhance IL-10 induced differentiation of functional 
CD4+ T regulatory cells (Tr1) (IL-10+, IFN-g+, IL-22/lo). Blanco et al (2005) 
showed that SLE patients with disease flares display greater proportions of 
perforin and/or granzyme B-positive lymphocytes with a differentiated effector 
phenotype (CCR72 and CD45RA+) (Blanco et al., 2001, Blanco et al., 2005). 
The administration of IFN-α/β to metastatic melanoma patients has also showed 
an increase of circulating fatally differentiated effectors (Di Pucchio et al., 2006). 
 
1.7 Apoptosis and SLE 
 
Apoptosis an active programmed cell death may be induced by a variety of 
soluble and surface signals (Mok and Lau, 2003).  Apoptosis is a process by 
which nuclear material may become a source of autoantigens which results in  
systemic autoimmunity, through defective clearance of dead and dying cells 
(Mok and Lau, 2003). For instance, in healthy individuals, apoptotic cells are 
promptly removed by macrophages in a process that is anti-inflammatory. 
However, it has been shown that in SLE patients, there is evidence of defective 
clearance of apoptotic cells (Munoz et al., 2009) leading to secondary necrosis. 
IFN promotes loss of self-tolerance, production of autoantibodies against 
nuclear material, and IC formation (Martin and Elkon, 2005). The process of IC 
formation between SLE autoantibodies and antigen derived from dead and 
dying cells can be replicated in vitro using apoptotic or necrotic debris. Evidence 
has shown that the ability of SLE sera to induce IFN-α production appears to be 
strongly correlated with the presence of antibodies against small nuclear 
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ribonucleoprotein particles (RNPs) such as Sm or U1RNP. Furthermore, the 
presence of antibodies specific for Sm, U1RNP, Ro, and dsDNA in serum has 
been linked with higher expression of interferon stimulated genes (ISGs) in SLE 
patients, supporting the clinical significance of these observations (Kirou et al., 
2005). 
 
1.8 Impaired clearance of immune complexes (antigen-antibody) in SLE 
 
Impaired clearance is the inability to completely eliminate apoptotic cell material 
which has been shown to contribute in the pathogenesis of SLE (Mok and Lau, 
2003). Deficiencies of early components of complement, such as C1q, C2 or 
C4 are rare, but they have been shown to be the strongest genetic susceptibility 
to SLE in humans, with a penetrance rate from 30% (C4 deficiency) to over 90% 
(C1q deficiency) (Walport, 2001, Manderson et al., 2004, Harley et al., 2006). 
A study carried out by Lood et al (2009) reported that circulating C1q inhibits 
formation of immune-complexes thus preventing activation of type 1 IFN-α 
production by pDC, suggesting a novel link between complement deficiency and 
the activation of the type I IFN pathway in SLE (Lood et al., 2009). Evidence 
has also shown that patients with SLE have relative deficiencies of the C3b/C4b 
receptor (CR1, CD35) on erythrocytes (E). This receptor is involved in the 
binding, transport and endocytosis of circulating immune complex bound 
complement components (ICC). Besides the influence of autoantibodies in SLE, 
the abnormalities in IC elimination are fundamental to the pathogenesis of SLE 
(Kavai, 2008). 
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1.9 SLE has a complex genetic basis 
 
SLE involves a combination of both environmental and genetic factors. Genetic 
components include a high sibling risk ratio (Fairhurst et al., 2008), high 
heritability (greater than 66%), and higher concordance rates between 
monozygotic twins (20 to 40%) compared to dizygotic twins (2 to 5%) (Deapen 
et al., 1992, Alarcon-Segovia et al., 2005). A large number of genetic risk factors 
are associated with increased susceptibility to SLE. The genetically determined 
increased risk status has been referred to as a “threshold liability” (Wandstrat 
and Wakeland, 2001), which is expected to be highly polygenic in nature and 
widely variable between individuals. Environmental factors also affect SLE 
susceptibility and likely interact with this “threshold liability” (Niewold et al., 
2010). Genetic contribution has been shown to be important in the development 
of the disease even though the concordance rate for SLE is only 25% among 
monozygotic twins (Rahman and Isenberg, 2008). More than 25 genetic risk loci 
have been identified in genome-wide association scans (GWAS). Interestingly, 
despite this remarkable progress, it is estimated that less than 10% of the total 
genomic susceptibility to SLE has been characterised (Moser et al., 2009). The 
genetic risk for SLE is likely derived from variation in many (perhaps as many 
as 100) genes, each of modest effect size with odds ratios between 1.15 and 
2.0 (Harley et al., 2009). 
 
1.10 Frequently observed alleles in SLE 
 
Studies have shown that HLA-DRB1, interferon regulatory factor 5 (IRF5) and 
signal transducer and activator of transcription 4 (STAT4) are the three most 
often observed alleles contributing each for a little more than 1% of the variance 
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in genome-wide association studies (GWAS) (Gateva et al., 2009). Together 
they contribute to the alterations in the innate and adaptive immune systems. 
IRF5 is the gene outside the HLA locus that is most strongly and consistently 
associated with SLE (Niewold et al., 2010). IRF5 is a transcription factor 
expressed in plasmacytoid dendritic cells (pDCs) and B-cells. It is involved in 
the transcription of type I interferon (IRF5 activates IFNα production) and pro-
inflammatory cytokines triggered by toll-like receptor 7 (TLR7), TLR8 and TLR9 
signalling (Armstrong et al., 2009). IRF5 acts as a downstream of TLR-MyD88 
signalling pathway in the induction of pro-inflammatory cytokines (Honda et al., 
2005, Takaoka et al., 2005). IRF5 polymorphisms have been observed in the 
pathogenesis of SLE and distinctive IRF-5 isoforms have been confirmed 
across different ethnic backgrounds (Lee and Song, 2009, Graham et al., 2007). 
STAT4 plays a vital role in type I and type II IFN signalling pathways 
(Obermoser and Pascual, 2010). It has been shown to involved in proliferation, 
differentiation, and apoptosis in SLE (Niewold et al., 2010). Evidence has shown 
a solid relationship between STAT4 and SLE in GWAS and candidate-gene 
studies (Deng and Tsao, 2010). As mentioned above, genetic susceptibility (risk 
alleles) plays a major role in the pathogenesis of SLE; STAT4 and IRF5 have 
been established as addition risk factors for SLE. 
 
Other studies have also shown that genes associated with SLE are involved in 
the following pathways as highlighted below (Gateva et al., 2009, Obermoser 
and Pascual, 2010):  
1. Antigen presentation to the T-cell receptor of CD4+ T-cells by HLA-DR1 
HLA-DR2 and HLADR3. 
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2. The pathways involved in upstream and downstream of type I IFN: (a) 
components of TLR signalling pathways (interleukin 1 receptor-
associated kinase 1 (IRAK1), IRF5, IRF7, IRF8, and tumour necrosis 
factor alpha-induced protein 3 (TNFAIP3)), (b) IFN signalling (STAT4), 
(c) intracellular DNA degradation (TREX1). 
3. Signalling molecules activated after engagement of the T-cell receptor 
(TCR; such as TNFSF4/OX40L, Programmed cell death protein 
1 (PDCD1), PTPN22, STAT4). 
4. Signalling molecules activated after engagement of the B-cell receptor 
(BCR; such as B-cell scaffold protein with Ankyrin repeats 1 (BANK1), B-
cell lymphocyte kinase (BLK), LYN, PTPN22) (Rieck et al., 2007, 
Arechiga et al., 2009). 
5. Molecules involved in the clearance of apoptotic debris and immune 
complexes, such as FCGR2A/CD32 and FCGR3A/CD16 (Coxon et al., 
1996). Additionally, C4A, C4B, C2 and C1Q. 
 
1.11 Dendritic Cells (pDCs) in the pathogenesis of SLE 
 
Dendritic cells (DCs) are antigen presenting cells that initiate adaptive immune 
responses. They are also capable of interacting with and influencing the 
responses of cells in the innate immune system. They are the initiators and 
regulators of immune responses (Steinman et al., 2003). It is believed that 
persistent activation of DCs could contribute to the pathogenesis of SLE 
(Banchereau and Pascual, 2006).  
In humans and other mammals, pDCs are specialised immune cells that 
selectively express TLR7 and TLR9, which are key endosomal sensors of 
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microbial and self-ribonucleic acid (RNA) or DNA, respectively (Liu, 2005, Gilliet 
et al., 2008). It was evidenced that the activation of TLR7 or TLR9 by nucleic 
acids in pDCs triggers signal transduction, resulting in rapid and vigorous 
secretion of type I IFN, inflammatory cytokines, and chemokines (Honda et al., 
2005, Gilliet et al., 2008). The TLR-induced IFN response is regulated by 
several immunoreceptor tyrosine-based activation motif (ITAM) bearing 
signalling receptors on pDCs (Blasius et al., 2006, Cao et al., 2009, Gilliet et al., 
2008).  
The above mechanisms play a fundamental role in the pathogenesis of SLE, 
although the definitive cause of SLE remains unclear. 
 
Tetherin 
 
This study focuses on measuring the level of tetherin using flow cytometry, 
compared to IFN-inducible gene expression measured by quantitative reverse 
transcription polymerase chain reaction (qRTPCR). 
Tetherin/CD317/HM1.24, also known as bone marrow stromal antigen 2 (BST-
2), is a lipid raft associated protein that in humans is encoded by the BST2 gene 
(Sauter, 2014, Mahauad-Fernandez et al., 2015). BST-2 was initially identified 
as a membrane protein in terminally differentiated human B-cells of patients 
with multiple myeloma (Goto et al., 1994, Ohtomo et al., 1999). It was later 
rediscovered as a potent antiviral restriction factor with the ability to tether 
enveloped viruses to the cell membrane of infected cells via its GPI anchor (Neil 
et al., 2008). It also potently inhibits virus replication in cultured cells and in vivo 
(Mahauad-Fernandez et al., 2014b, Mahauad-Fernandez et al., 2015). BST-2 
is an alpha interferon-inducible cellular molecule that impairs and/ or inhibits the 
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release of Human immunodeficiency virus type 1(HIV-1) and other enveloped 
viruses (Neil et al., 2008, Van Damme et al., 2008) (Figure 3). It functions as a 
negative-feedback regulator of IFN production by pDCs (Bego et al 2012). BST-
2 has been stated to consists of an N-terminal transmembrane region, a central 
coiled coil motif, and a putative C-terminal glycosylphosphatidylinositol (GPI) 
anchor motif (Kupzig et al., 2003, Andrew et al., 2011, Sauter, 2014) (Figure 2). 
It is a 30-36 kDa type II transmembrane protein that consists of 180 amino acids 
(Ishikawa et al., 1995). The BST-2  ectodomain encodes three cysteine 
residues (Goto et al., 1994, Andrew et al., 2009, Perez-Caballero et al., 2009)), 
which are believed to autonomously contribute to the formation of covalent 
cysteine-linked dimers (Andrew et al., 2009, Perez-Caballero et al., 2009). BST-
2 inhibits virus release by physically tethering viral particles to the cell surface 
via its TM motif and GPI anchor. This protein is constitutively expressed in 
mature B cells, plasma cells and pDCs, and in many other cells; but only as a 
response to IFN stimulation. This study will investigate the role of tetherin in the 
pathogenesis of SLE.  
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Figure 2: BST-2 structure 
 
BST-2 is a type II transmembrane protein with a N-terminal cytoplasmic tail (CT) , a 
transmembrane domain (TM), a coiled-coil domain and a glycosylphosphatidylinositol (GPI) 
anchor embedded in lipid rafts in the cell membrane (Mahauad-Fernandez and Okeoma, 2016). 
The amino acid sequence of BST-2 depicted in the grey box is colour coded with their respective 
domains. Numbers on top of amino acids correspond to amino acid location. Underneath the 
amino acid sequences are colour boxes corresponding to different functions and characteristics 
of BST-2 as shown on the left corner of the Fig2. BST-2 contains two translational start sites at 
methionine 1 and 13 (red) generating a long and short isoform, respectively (Mahauad-
Fernandez and Okeoma, 2016). The short isoform cannot induce NF-kB activation since it lacks 
the YXY motif. BST-2 forms homo-dimers and tetramers through three conserved cytosine 
residues at positions 53, 63 and 91. Leucine residues at positions 70 and 123 are important for 
maintaining the structure of BST-2 and for virus tethering, which also requires the C-terminal 
GPI anchor. Taken from Mahauad-Fernandez and Okeoma, 2016. The role of BST-2/Tetherin 
in host protection and disease manifestation, Immunity, Inflammation and Disease; 4(1): 4-
23. 
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1.12 The Tetherin Protein and Mechanism of Virion Retention 
 
BST-2 was rediscovered in 2008 as the host agent responsible for preventing 
and/or inhibiting the release of HIV-1 with mutated viral protein U (Vpu) from 
host cells (Neil et al., 2008, Van Damme et al., 2008); and it was later  renamed 
tetherin (Neil et al., 2008). HIV-1 counteracts the antiviral function of BST2 by 
expressing VPU (Neil et al., 2008, Van Damme et al., 2008). However, in the 
absence of VPU, virus particles are prevented from budding off the cellular 
membrane in cells that express BST-2, resulting in virions being tethered to the 
plasma membrane (Figure 3) (Neil et al., 2008). By tethering enveloped viruses, 
BST-2 prevents virus release which in return stimulates and amplifies innate 
immune responses through the induction of cytokine/ chemokine expression 
(Galao et al., 2012, Mahauad-Fernandez et al., 2014b). This process is believed 
to largely involve BST-2 cytoplasmic tail (Mahauad-Fernandez and Okeoma, 
2016). It is not clear whether BST-2 acts as the actual tether or whether BST2- 
dependent tethering occurs in all BST-2 expressing cell types (Miyagi et al., 
2009). BST-2 was shown to be induced by type I, type II  and type III IFNs 
(Blasius et al., 2006), suggesting that BST-2 is part of the innate antiviral 
response triggered in infected cells. 
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Figure 3: The mechanism of tetherin as an antiviral molecule 
 
A, In macrophages and in interferon-stimulated CD4+ T-cells, the antiviral membrane protein 
tetherin (also known as M1.24, BST2 or CD317) becomes incorporated into the nascent virion. 
However, the parallel tetherin dimers do not inhibit viral assembly and membrane scission; they 
are thought to form physical crosslinks between the cell and the virion by virtue of their dual-
membrane anchors (Martin-Serrano and Neil, 2011). This leads to virion accumulation on the 
cell surface and subsequent internalisation to late endosomes. B, Primate immunodeficiency 
viruses encode countermeasures that interact with tetherin (Vpu for HIV-1, Nef for most simian 
immunodeficiency viruses (SIVs) and envelope glycoprotein (Env) in the case of HIV-2). These 
interactions can be species specific and result in inhibition of the antiviral activity of tetherin, 
often accompanied by cell surface removal of the protein, its intracellular sequestration and, 
ultimately, its degradation (Martin-Serrano and Neil, 2011). Image was from 
http://www.nature.com/nrmicro/journal/v9/n7/fig_tab/nrmicro2596_F4.html.  
 
 
BST-2 is underrepresented in plasma membranes from cells expressing VPU 
(Douglas et al., 2009) and also the K5 protein of Kaposi’s sarcoma-associated 
herpesvirus (KSHV) (Bartee et al., 2006). K5 is a viral homologue of the cellular 
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transmembrane ubiquitin ligases, called membrane-associated RING-CH 
(MARCH) proteins (Bartee et al., 2004), which mediate the ubiquitination of the 
cytoplasmic portion of the transmembrane proteins (Nathan and Lehner, 2009). 
Each member of this family targets a subset of cellular membrane proteins with 
both unique and shared specificities (Bartee et al., 2006, Wang et al., 2008). 
The downregulation of BST2 by K5 suggests that K5 also counteracts innate 
antiviral responses (Mansouri et al., 2009). Studies have shown that most 
transmembrane proteins targeted by viral or cellular MARCH proteins are type 
I transmembrane proteins of the immunoglobulin superfamily; whereas, BST2 
is a type II transmembrane protein (Kupzig et al., 2003).  
 
pDC activation and IFN production are associated in autoimmune diseases 
therefore a mechanism controlling pDC IFN production is essential (Cao et al., 
2009). Activation of TLR7 and / or TLR9 by nucleic acids in pDCs triggers signal 
transduction, resulting in rapid and abundant secretion of type I IFN, 
chemokines and inflammatory cytokines (Honda et al., 2005, Gilliet et al., 2008). 
A study carried out by Cao et al (2009) identified BST2 as a physiological ligand 
for a human pDC-specific receptor immunoglobulin-like transcript 7 (ILT7) (Cao 
et al., 2009). They also discovered that pDCs play an important role in antiviral 
innate immune responses by secreting large quantities of IFN-α/β. BST2-ILT7 
interaction, serves as an important negative feedback mechanism to prevent 
prolonged IFN production after viral infection (Cao et al., 2009). Despite BST-2 
antiviral functions, it is believed to be involved in SLE disease manifestation, a 
function associated to the ability of BST-2 to encourage cell to cell interaction 
(Mahauad-Fernandez and Okeoma, 2016). 
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Looking at the above mechanisms that contribute to the development of SLE, 
there is clearly a need for an accurate assay and the discovery of new 
biomarkers for routine clinical practice. There has been extensive investigation 
on the understanding of SLE pathogenesis and only a few biomarkers have 
been validated and widely accepted (Liu et al., 2005). However, there is a lack 
of reliable, specific biomarkers for SLE which can precisely assess disease 
activity, identify patients at risk for flares and organ damage and aid in the 
management of patients. Severe flares of disease may occur unpredictably, and 
markers of response to therapy are needed to guide the effective use of 
immunosuppressant drugs and glucocorticoids.  Despite the fundamental role 
played by IFN in pathogenesis, there is currently no assay for IFN used in 
routine clinical practice.  Additionally, accurate tests for IFN activity are needed 
to stratify patients for IFN-blocking biologics, and achieve highest response 
rates. 
 
1.13 Biomarkers for SLE 
 
There has been extensive effort and devotion to approach the several 
challenges of SLE including the development of diagnostic tests and biomarkers 
to inform the clinical management of SLE patients (Liu et al., 2013). The 
investigations for SLE (lupus) biomarkers to diagnose, stratify, monitor, and 
predict an individual’s response to therapy has been remarkable. However, 
there are still numerous unmet needs in SLE research and patient care (Liu et 
al., 2013). These are largely due to the lack of reliable lupus biomarkers for 
diagnosis, stratification, monitoring, and prediction of response to treatment (Liu 
et al., 2013). A biomarker is defined as ‘‘a measurement, including but not 
  
Page 45 
 
  
limited to a genetic, biochemical, molecular, biological, or imaging event whose 
alterations correlate with the pathogenesis and/or manifestations of a disease 
and can be evaluated quantitatively and/or qualitatively in laboratories’’ (Illei et 
al., 2004a, Illei et al., 2004b). 
SLE biomarker reports have been published during the past years; however, 
the majority of these studies were carried out on small numbers of patients and 
they have been limited to cross-sectional observations.   
The development of biomarkers has improved diagnosis and monitoring of the 
disease, however, there is no specific biomarker. This is the reason why, 
researchers have evolved toward the discovery and validation of lupus 
biomarker ‘panels’ for diagnosis and disease activity monitoring (Liu et al., 
2013).  
 
This project will focus on investigating a biomarker and developing an accurate 
assay for SLE diagnosis and/or prognosis. The purpose of the biomarker is to 
assist in making a precise diagnosis and/or monitoring disease activity, which 
may help in predicting the onset of SLE in susceptible individuals and/or 
development of flares in patients with established SLE. It will also aid in 
assessing the effectiveness of therapeutic interventions. If the outcomes of the 
findings are successful and reproducible this may allow the proactive institution 
of therapeutic and preventive strategies so that the therapeutic efficacy can be 
improved with minimised side effects. 
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1.14 Discovery  
 
A previous study by Dr Vital’s group in Leeds (El-Sherbiny et al., 2016) 
speculated that changes in numbers of strongly IFN-stimulated gene signature 
(IFNGS) positive populations, such as B-cells, which are characteristic of 
autoimmunity, could lead to falsely positive or negative IFNGS analysed using 
whole blood. They performed a gene expression analysis of unsorted peripheral 
blood mononuclear cells (PBMCs) and sorted cell subsets, with B-cells that 
were physically sorted and analysed separately by gene expression. This 
demonstrated a positive IFNGS, which was not apparent if the whole blood 
unsorted sample was analysed. The greatest contribution to overall IFNGS 
status was made by monocytes, which have both highest expressions of 
interferon-inducible genes as well as being a large proportion of PBMCs. 
 
Cell sorting is not feasible as a diagnostic test so they therefore sought a cell 
surface protein marker that represents IFN activity to allow analysis of individual 
populations conveniently using flow cytometry. Tetherin was found to be 
expressed on all blood cell types and whose level corresponds to subset-
specific gene expression IFNGS (El-Sherbiny et al., 2016). 
In cross sectional studies, Tetherin was measured on several circulating cell 
subsets and compared to disease activity as well as plasmablast numbers 
(another biomarker of B cell activity and disease activity in research studies). 
Memory B cell tetherin was shown to correlate better with these parameters 
than tetherin on monocytes or interferon-stimulated gene expression (El-
Sherbiny et al., 2015). This is consistent with the prominence of B-cells in 
models of SLE pathogenesis. 
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Our group developed and clinically validated a 2-score system (IFN-Score-A 
and -B) using Factor Analysis of 30 ISGs measured by TaqMan selected from 
3-IFN annotated modules. These scores were evaluated using in-vitro IFN 
stimulation as well as in sorted cells and they were then clinically validated in a 
cohort of 328 autoimmune disease patients and healthy controls. ISGs varied 
in response to IFN-subtypes and both scores varied between cell subsets. 
However, IFN-Score-A differentiated Systemic Lupus Erythematosus (SLE) 
from both Rheumatoid Arthritis (RA) and Healthy Controls (HC), while IFN-
Score-B differentiated SLE and RA from HC (El-Sherbiny et al., 2015). In SLE, 
both scores were associated with cutaneous and haematological but not 
musculoskeletal disease activity. Due to these outcomes, Score A would be 
compere against tetherin expression level on the cell subsets. 
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1.15 Hypothesis  
The overall hypothesis of this study is: flow cytometric assessment of tetherin 
will provide a convenient assay for Type I interferon activity that has clinical 
utility. I will investigate this under the following sub-hypotheses: 
 
Hypothesis 1: Cell surface tetherin can be measured accurately using a whole 
blood assay in a routine diagnostic laboratory. 
 
Hypothesis 2: Tetherin will differentiate SLE from Healthy control 
 
Hypothesis 3: SLE patients in remission with higher level of tetherin on 
memory B cells have significantly higher risk of flare compare to patients in 
remission with lower or normal level of tetherin. 
 
Hypothesis 4: SLE patients who are flaring will show a reduction in tetherin 
level following treatment. 
 
Hypothesis 5: Tetherin may have value as part of a biomarker panel to select 
patients for targeted therapy. 
 
1.16 Aims 
 
To validate a flow-cytometry based assay for IFN activity as a clinically 
useful biomarker in SLE. 
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1.17 Objectives 
 
In order to test my hypothesis I will: 
 
1. Optimise a whole blood assay for tetherin in a routine clinical laboratory 
and compared to isolated peripheral blood mononuclear cells (PBMCs) 
assay results.  
 
2. Collect a cross-sectional sample of SLE patients (and healthy controls) 
through Leeds SLE clinic via the standard pathology blood service and 
measure tetherin by flow cytometry. I will also collect diagnosis and 
treating physician opinion of flare or remission as well BILAG disease 
activity score and extract RNA and perform an existing interferon-
stimulated gene expression score as an alternative interferon biomarker 
for each analysis.  
 
3. Collect flare rate in follow up for patients in remission at the time of initial 
sampling 
 
4. Evaluate tetherin as an ‘‘IFN high’’ biomarker (for interferon-blocking 
therapy) alongside the criteria for an alternative biologic therapy 
(belimumab). 
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2.0 Materials and methods 
 
2.1 Ethical Considerations 
As the project involved acquiring human blood samples, it was necessary to 
obtain ethical approval before the project could commence. Ethical approval 
was provided by Leeds East National Research Ethics committee, approval 
reference number (REC 10/H1306/88).  
 
In order to minimise distress to the patients, blood samples for the study were 
collected during venepuncture carried out as part of routine clinical care. For 
collection of blood from both the patients and healthy controls, samples were 
collected in ethylenediaminetetraacetic acid (EDTA) tubes. Samples collected 
were used for cell surface phenotyping (whole blood lysis) and PBMC isolation 
and were used within 24 hours of collection. For whole blood lysis and staining 
5 mL of EDTA blood samples were sent to the laboratory for each patient and 
control. Samples were stored at 4oC. All data related to the study were stored 
on password protected computer systems. 
 
2.2 Patients and Control Selection 
 
Patients with an established diagnosis of SLE were identified from the Leeds 
Teaching Hospitals NHS Trust connective tissue clinic in Leeds, and 
categorised as in remission or flare according to BILAG 2004 and by physicians 
treating. Informed written consent was obtained from patients and suitable 
healthy volunteers.  
Samples obtained from patients were divided in two groups as follows: 
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1. For SLE patients in remission, can Cell-Specific Interferon Marker 
(CSIM) predict flare in subsequent 12 months (n=80 patients). 
2. For new onset SLE or undifferentiated connective tissue disease (CTD), 
can CSIM predict progression to further organ involvement (n=40 
patients). 
3. For SLE patients with current flare who start treatment, is CSIM 
responsive (n=40 patients).  
 
2.3 Preliminary Investigation whole blood assay: titrations, template and 
compensations    
 
2.3.1 Equipment and consumables  
 
FACSCanto II Flow Cytometer (Diva 7 software) (Becton Dickinson), FACS flow 
tubes (Becton Dickinson) 50 mL Falcon tubes (Becton Dickinson), 
haemocytometer, light microscope, laboratory booking in forms, laboratory 
coat, gloves disposable (Regional Supplies Dept), goggles coverall (BDH). 
Pastettes (Regional Supplies Dept), Eppendorf pipette 0.5-10 µL, Eppendorf 
pipette 200-1000 µL. Pipette tips polypropylene 5-100 µL yellow, pack of 1000 
(Regional Supplies Dept). Pipette tips polypropylene 200-1000 µL blue, pack of 
100 (Regional Supplies Dept). Monoclonal antibodies and isotypes, (Miltenyi 
Biotec and Biolegend). 
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2.3.2 Antibody optimisation 
 
The optimal antibody concentration was determined experimentally for each 
antibody by using a series of dilutions of antibodies. Blood samples from two 
healthy volunteers were used. Eight antibodies were used for this project (Table 
3) and for each antibody six FACS flow tubes (Becton Dickinson) were labelled 
with the antibody (Miltenyi Biotec and Biolegend) and the volume to be added 
into the tubes for the titration method. The antibody volume (0 µL, 1 µL, 2.5 µL, 
5 µL, 7.5 µL and 10 µL) was carefully pipetted into the correct test tube. The 
samples were processed as described in 2.3.3. 
 
2.3.3 Preparation of lymphocytes for whole blood lysis staining  
 
50 mL Falcon tubes (Becton Dickinson) were labelled with the patients’ or 
healthy volunteers’ initials. The blood samples were mixed well and 4 mL of 
healthy sample (EDTA whole blood) was added into the appropriate Falcon tube 
and 46 mL of the freshly prepared working red blood cells (RBCs) lysing buffer 
was added (working RBCs lysing buffer was prepared as manufacturer 
recommendation catalogue number 349202 (Becton Dickinson) diluted 1:10 
with distilled water)). The tubes were vortexed and incubated for 10 min at room 
temperature and were subsequently centrifuged at 500 g for 10 min. The 
supernatant was decanted. The cells were suspended and  washed by adding 
50 mL of Phosphate-buffered saline / 1% foetal bovine serum (%PBS / FBS) 
solution (FACS wash buffer) into the Falcon tube; and the tubes were 
centrifuged at 500 g for 10 min. The washing procedure was repeated. After 
centrifugation 50 mL of 1% PBS / FBS wash buffer was added into the Falcon 
tubes and the samples were mixed gently by inversion and 10 µL of the sample 
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was pipetted into the haemocytometer and the cells were counted using 
haemocytometer and light microscope and the cells number recorded. After 
cells were counted for each sample, the tubes were centrifuged at 500 g for 10 
min.  
 After centrifugation, supernatant was decanted. Cells were resuspended in 
blocking buffer (composed of IgG from human serum (appendix 1)) at a cell 
density of 20 million/mL and left for 5 min at room temperature. 50 µL of the 
cells was added into the series of dilutions of antibodies, 0 µL, 1 µL, 2.5 µL, 5 
µL, 7.5 µL and 10 µL (Table 3). The antibodies were pipetted to the bottom of 
the FACS flow tubes and the pipette tip was changed for each antibody. The 
tubes were mixed gently by vortexed for 3 s and tubes were incubated for 30 
min at 4°C; samples were protected from direct light. The cells were 
subsequently washed by adding 3 mL of 1% PBS / FBS into each tube, then 
vortexed and centrifuged at 500 g for 5 min. Supernatants were decanted and 
the washing procedure repeated. The cells were then resuspended in 400 µL 
cell fix buffer (PBS + 0.5% formaldehyde). The tubes solution were mixed and 
left in ice for 10 min, to prevent the formation of aggregates. The samples were 
acquired on FACSCanto II Flow Cytometer (Diva 7 software). The samples 
were acquired at threshold of 50,000 events per sample tube (Figure 4). The 
voltages of the forward scatter and side scatter were set using the unstained (0 
µL) tube.  
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Antibodies used for cellular staining list were added into each tube as listed  
Antigen Isotype Fluorochrome Manufacturer   Clone 
 
CD27 
 
 
 
CD19 
 
 
 
 
CD38 
 
 
 
 
CD8 
 
 
 
 
CD56 
 
 
 
 
CD3 
 
 
 
 
CD4 
 
 
 
CD317 
 
Mouse IgG1κ 
 
 
 
Mouse IgG1 
 
 
 
 
Recombinant 
human IgG 
 
 
 
Mouse 
IgG2a 
 
 
 
Recombinant 
human IgG 
 
 
 
Mouse 
IgG2a 
 
 
 
Mouse 
IgG2a 
 
 
Mouse IgG1κ 
 
Viobright FITC 
 
 
 
VioBlue 
 
 
 
 
PE-vio770 
 
 
 
 
PerCP-Cy5.5 
 
 
 
 
APC 
 
 
 
 
VioGreen 
 
 
 
 
APC-Vio770 
 
 
 
PE 
 
Miltenyi Biotec (cat 
 #130-104-845) 
 
 
Miltenyi Biotec (cat  
# 130-098-598) 
 
 
Miltenyi Biotec (cat 
# 130-108-838) 
 
 
 
Miltenyi Biotec (cat # 
130-094-972) 
 
 
 
Miltenyi Biotec (cat # 
130-100-698) 
 
 
 
Miltenyi Biotec (cat 
# 130-096-910) 
 
 
 
Miltenyi Biotec (cat # 
130-096-652) 
 
 
 
Biolegend (cat # 
348406) 
 
M-T271 
 
 
 
LT19 
 
 
 
REA572 
 
 
 
 
BW135/80 
 
 
 
 
REA196 
 
 
 
 
BW264/56 
 
 
 
 
VIT4 
 
 
 
 
RS38E 
Table 3: Antibodies and volumes used for titration procedure 
 
2.3.4 Data analysis for titration  
 
During acquisition, the cell populations (lymphocytes, monocytes and 
neutrophils) were identified by their light scatter using forward side scatter 
(FSC) and side scatter (SSC), and voltages were adjusted to determine the cell 
populations (Figure 4). Voltages were set using unstained cells.  On the 
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lymphocytes population a gate was drawn (P1) which helped with determining 
the population on the second dot plot SSC against CD19 VioBlue (Figure 4). 
The positive and negative population, were defined by quadrant gating in the 
dot plots and interval gates on histogram plots (Figure 4). The procedure was 
repeated for the remaining antibodies (Table 3). Statistical analysis was 
acquired of the data corresponding percentage (%), mean fluorescence 
intensity and median fluorescence intensity as shown in (Figure 4). 
 
Figure 4 shows titration analysis between unstained and stained 
 
 Fig 4: A snap shot of the titration analysis procedure. A, shows the unstained tube. B shows 
the stained tube (5 µL) of CD19. The voltages of the forward scatter and side scatter to 
determine the cells population. The other antibodies population were determined in a similar 
manner. The % parent, mean and median was determined by P2 = the positive population 
stained by antibody plot on the histogram, as showed above. The statistical analysis generated 
the mean and median values. 
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Figure 5 : Monoclonal antibodies titration as part of optimisation process. 
 
Fig 5: Titrations: Image A-H shows the series of titration of the antibodies. 10 µL was 
recommended by the manufactures; however, after titration and data were plotted we decided 
to use 5 µL for each antibody. This volume will deduce accurate and reliable results at a reduced 
cost. 
 
Figure E, F, G and H shows an increased above 5 µL, however, 5 µL was used 
in the study. This was because the negative population bleed (spread) into the 
positive population. We found that 5 µL / 50 µL staining buffer was effectively 
saturating the cells for staining and maintain MFI, noting that manufacturer 
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recommended dose was equivalent to my finding (10 µL per 100 µL staining 
buffer for 10 million cells maximum) (Table 4 and Figure 5) a template was 
created (Figure 6) to assess the phonotype of B-cells, T-cells and Natural Killer 
(NK) cells. Compensation was carried out to ensure there is no bleeding in other 
channels (Figure 7and Figure 8). 
 
2.3.5 Preparing compensation control samples 
 
Compensation control samples were prepared, processed and acquired as 
described previously in 2.3.3. However, with the compensation control samples, 
eleven FACS Flow tubes were labelled; eight tubes for the single stain, one 
unstained, one Isotype (ISO) and one test. The Test tube had all eight 
antibodies and single stain tubes had one antibody into each tube (Table 4). 
The antibodies were pipetted into the bottom of the FACS Flow tubes. The test 
tube had premade cocktail of antibodies of 40 µL. An ISO (Miltenyi Biotec) 
cocktail of corresponding antibodies (40 µL) was added into the labelled ISO 
tube.  
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Antibodies were added into each tube as listed below into the labelled test tube 
Monoclonal 
antibody 
Monoclonal Fluorochrome Manufacturer   Clone Volume 
per test 
(µL) 
Human 
CD27 
 
 
 
Human 
CD19 
 
 
 
Human 
CD38 
 
 
 
 
Human 
CD8 
 
 
 
Human 
CD56 
 
 
 
 
Human 
CD3 
 
 
 
Human 
CD4 
 
 
 
Human 
CD317 
Mouse IgG1κ 
 
 
 
 
Mouse IgG1 
 
 
 
 
Recombinant 
human IgG 
 
 
 
 
Mouse 
IgG2a 
 
 
 
Recombinant 
human IgG 
 
 
 
 
Mouse 
IgG2a 
 
 
 
Mouse 
IgG2a 
 
 
 
Mouse IgG1κ 
Viobright 
FITC 
 
 
 
VioBlue 
 
 
 
 
PE-vio770 
 
 
 
 
 
PerCP-Cy5.5 
 
 
 
 
APC 
 
 
 
 
 
VioGreen 
 
 
 
 
APC-Vio770 
 
 
 
 
PE 
Miltenyi 
Biotec (cat 
 #130-104-
845) 
 
Miltenyi 
Biotec (cat  
# 130-098-
598) 
 
Miltenyi 
Biotec (cat 
# 130-108-
838) 
 
 
Miltenyi 
Biotec (cat # 
130-094-972) 
 
 
Miltenyi 
Biotec (cat # 
130-100-698) 
 
 
 
Miltenyi 
Biotec (cat 
# 130-096-
910) 
 
Miltenyi 
Biotec (cat # 
130-096-652) 
 
 
Biolegend 
(cat # 
348406) 
M-T271 
 
 
 
 
 
LT19 
 
 
 
 
REA572 
 
 
 
 
BW135/
80 
 
 
 
 
REA196 
 
 
 
 
BW264/
56 
 
 
 
 
VIT4 
 
 
 
RS38E 
5 
 
 
 
 
 
5 
 
 
 
 
5 
 
 
 
 
 
5 
 
 
 
 
5  
 
 
 
 
 
5 
 
 
 
 
5 
 
 
 
5 
Table 4: Monoclonal antibodies and volumes used to process or stain the 
labelled test tubes  
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Acquisition of sample- Samples were acquired and recorded on the SLE 
template panel. 
Panel  Stopping GATE 
Population 
Number to acquire 
Singles stained 
 
Unstained 
 
Iso 
 
Test panel 
Lymphocytes 
 
Lymphocytes 
 
Lymphocytes 
 
CD19+ 
50,000 events 
 
50,000 events 
 
50,000 events 
 
30,000 events 
Table 5: Results were recorded on this format and then exported as an 
experiment or FCS files for backup. 
 
Figure 6- Acquisition template, shows a snap shot of the labelled test tube after 
compensation had been carried out. 
 
Fig 6: A screen shot of the SLE panel template of whole blood staining. The dot plot shows the 
identification of naïve and memory B-cells, plasmablasts, CD3+ T-cells, NK-cells and 
monocytes. The histogram represents the intensity level of tetherin protein present in each of 
these cell types.  
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2.3.6 Compensation analysis 
 
Compensation was carried out to correct for the signal spillover from a given 
fluorochrome into the neighbouring channels (Figure 7 and Figure 8). To correct 
spillover, spectral overlap values were adjusted for all fluorophores and in all 
detectors, via single-colour controls. Compensation was performed either by 
decreasing or increasing the values in equation. As indication of good 
compensation, the mean/median fluorescence intensities (MFIs) of the positive 
and negative populations of the compensation control were aligned in the 
neighbouring channels (Figure 8). Compensation was correctly set when the 
median of the negative population is equal to the median of the positive 
population in the spillover channel.  
The procedure was repeated after each fluorochrome that was compensated. 
Compensated fluorochromes were saved on the cytometer settings and on to 
the tubes, to ensure each fluorochrome was compensated against each other 
(Figure 8). Fluorescent minus one (FMO) were run once to ensure appropriate 
gating positioning. 
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Figure 7 and Figure 8 shows a snap shot of how compensation was performed. 
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Figure 8 shows how each antibody is compensated against the other 
antibodies. 
 
Fig.8. A snap shot of a manually compensated CD317 PE against all eight antibodies. The SSC 
and FSC voltages were set with unstained sample. Antibodies were compensated by clicking 
on the cytometer window compensation and adjusted the Spectral Overlap, either by 
decreasing or increasing the values as some antibodies were either under or over 
compensated.  This process was repeated for each antibody.  
 
2.4 Main study methods 
 
 
2.4.1 Preparing patients’ whole blood samples for flow cytometry 
 
Patients’ samples were prepared and acquired as described previously in 2.3.3 
However, quality control single labelled cells (single staining) was performed 
every two months or when a new vial was opened. Unstained, Isotype control 
stained, and Test staining were performed (processed) for every sample 
processed. Figure 6 shows a representation of a test sample. 
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2.4.2 Isolation of peripheral blood mononuclear cells (PBMCs) from 
whole blood using Leucosep Barrier Ficoll Tube 
 
Figure 9 PBMCs separation  
 
Fig 9: Snapshot of PBMCs separation procedures 
 
The required numbers of Leucosep tubes were left at room temperature (25-
30°C) prior to use. Prior to the isolation of PBMCs from whole blood specimens, 
the Leucosep Barrier Ficoll tubes and the 50 mL Falcon tubes were labelled 
with patients’ identifiers on the tubes and on the lids, obtained from the 20 mL 
of EDTA whole blood. The whole blood samples were thoroughly mixed before 
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adding into the appropriate Leucosep Barrier Ficoll tube and were diluted at a 
ratio of 1 part blood to 2 parts PBS solution.  Leucosep Barrier Ficoll tubes were 
centrifuged at 800 g at 20oC for 15 min in a bucket and rotor centrifuge 
(Eppendorf). After centrifugation, three layers occurred above the barrier: a 
plasma layer, the interphase containing the PBMCs and a small layer of Ficoll 
(Figure 9). The plasma layer was aspirated. The whitish buffy coat (PBMCs) 
formed in the interphase was carefully aspirated into the appropriate Falcon 
tubes. PBMCs were washed three times with PBS, centrifuged at 500 g at 20oC 
for 10 min the procedure was repeated twice. The cells were checked for 
remaining red blood cells (RBCs). If RBCs were present (reddish pellet), freshly 
prepared RBCs lysing buffer was added ((Becton Dickinson) dilute to 1/10 with 
distilled water) to lyse the RBCs. The cells were mixed thoroughly and left for 
10 min at room temperature; tubes were centrifuged at 500 g at 20oC for 10 min 
and washed twice with PBS. 
The cells were counted using the TC20 automated cell counter (BioRAD) and 
stained as described in 2.3.3. The remaining PBMC cells were lysed using 250 
µL RNA lysis buffer as manufacturer recommendation (RNA lysis buffer; 1000 
µL of RNA lysing (RL) buffer (Norgen Biotec) and 10 µL of β-Mercaptoethanol 
(MJ148-9m) using RNAse free tips applied in appropriate labelled Eppendorf 
tubes and stored at -20oC for short-term (2-4 weeks) and at -80oC for long-term 
storage (6 months). 
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2.4.3 RNA extraction: procedure for Purifying Total RNA using Norgen’s 
Animal Tissue RNA Purification Kit 
 
Figure 10 RNA extraction procedures 
 
Fig10: Steps involved in RNA extraction. Norgen’s Animal Tissue RNA Purification Kits were 
used. Norgen’s Animal Tissue RNA Purification Kit provides a rapid method for the isolation 
and purification of total RNA. 
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As described in 2.4.2 the stored cells were defrosted and 600 µL of RNase-Free 
Water and 20 µL of reconstituted Proteinase K was added to the lysate, 
vortexed and was incubated at 55oC for 5 min. The tubes were vortexed 
occasionally during incubation. The lysate was spun at 14,000 g for 1 min using 
a benchtop microcentrifuge. The supernatant was transferred into an RNase-
free microcentrifuge tube and 450 µL of 100 % ethanol was added to the lysate 
and the tubes were vortexed. After cell lysate preparation RNA was bound to 
column by assembled a column for each sample with collection tubes; 650 µL 
of the lysate with the ethanol was added onto the column and centrifuged at 
4000 g for 1 min. If the entire lysate volume had not passed, the tubes were 
spun for an additional min at 14,000 g. After centrifugation the flow-through was 
discarded and the spin column with its collection tube was reassembled. 
Depending on the lysate volume the above procedures were repeated.  
Wash Solution A (400 µL) was added to the column and centrifuged at 4000 g 
for 2 min. The flow-through was discarded and the spin column with a new 
collection tube was assembled. After centrifugation, 100 µL of Enzyme 
Incubation Buffer A and 15 µL of DNase I was added to the column and the 
tubes were centrifuged at 14, 000 g for 1 min. (Note: if the entire 115 µL of 
DNase mix did not pass through the column it was centrifuged at 14,000 g for 
an additional min). After centrifugation the flow-through that was present in the 
collection tubes was pipetted back onto the top of the column and incubated at 
room temperature for 15 min.  
After incubation, 400 µL of wash solution A was added to the column containing 
the DNase I mix and centrifuge at 14,000 g for 1 min. (Note: if the entire 115 µL 
of DNase mix did not pass through the column, it was centrifuged at 14,000 g 
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for an additional min). The flow-through was discarded and the spin column with 
its collection tubes was reassembled. The column wash was repeated. After the 
second wash the column was spun for 2 min in order to thoroughly dry the resin. 
The collection tubes were discarded. The columns were placed into a fresh 1.7 
mL Elution tube provided with the kit. 50 µL of Elution Solution A was added to 
the column. The tubes were centrifuged at 200 g for 2 min, followed by 1 min at 
14,000 g (Note: if the entire 50 µL has not been eluted, the column was 
centrifuged at 14,000 g for 1 additional minute).   
 
2.4.4 Quantitation of Isolated RNA 
 
The concentration and purity of the RNA samples were determined or assessed 
using the NanoDrop 1000 Spectrophotometer. The ratio absorbance of the RNA 
samples was measured at 260 nm and 280 nm against corresponding diluent 
buffer; the readings were obtained and recorded. The concentration of nucleic 
acid (RNA) was determined using the Beer-Lambert law, which predicts a linear 
change in absorbance with concentration. RNA purity was determined at 
A260/A280 of 2 at a ratio of 1.8 - 2.0. The purified RNA Samples were stored 
at -20oC for a few days. Samples were placed at -80oC for long term storage 
prior to use on a 96.96 chip (TaqMan). 
 
2.4.5 Gene Expression PreAmp with Fluidigm® PreAmp Master Mix and 
TaqMan® Assays 
This method was carried out according to the manufacturer (Fluidigm) user 
guide (PN 68000088 J1) instructions: 
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2.4.5.1 Reverse Transcription 
 
The purified Total RNA obtained from RNA extraction (2.4.3) was converted in 
to complementary DNA (cDNA) by reverse transcription with 96.96 reactions. 
Reverse transcriptase (RT) master mix and RNase free water were mixed in a 
tube (Table 6) and 1 µL RNA was added. 4 µL of the mixed solution was added 
into each well of the microtiter plates and then incubated (Table 7). 
 
RT mix component 1 x (µL) 106 
RT master mix 
RNase-free water 
RNA 
Total volume 
Volume of mix used per well 
1 
3 
1 
5 
4 
106 
318 
 
424 
 
 
Table 6: solutions used for reverse transcription 
 
Below are the incubation temperatures and times involved for converting RNA 
into cDNA 
Step  oC Time 
 
Reverse transcribe 
Denature enzyme 
Hold 
Total (exclude hold) 
25 
42 
85 
4 
5 min 
30 min 
5 min 
Hold 
45 min 
Table 7: Incubation steps for transcribing RNA into cDNA (single stranded 
DNA).  
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2.4.5.2 Pooling the TaqMan Gene Expression Assays 
 
In a microcentrifuge tube, equal volumes (2 µL) of each 20x Taqman gene 
expression assay were combined for the 96 assays chip. The pooled assays 
were diluted using 8 µL DNA Suspension Buffer (10 mM Tris, pH 8.0, 0.1 mM 
EDTA; TEKnova, PN T0221) to ensure each assay was at a final concentration 
of 0.2x (180 nM). These volumes were multiplied by three for the final working 
solutions. 
 
2.4.5.3 Preparing Sample Pre-Mix and Samples 
 
A pre-mix was prepared for the reactions as shown in the table below (Table 8). 
The pre-mix (3.75 µL) was aliquoted for each sample in a PCR plate and kept 
on ice. 1.25 µL of cDNA obtained from the step above (RT) was added into each 
well containing pre-mix. The plate was vortexed for 10 s and centrifuged at 500 
g for 1 min. 
 
Component Volume / Volume for 96  
  Reaction (µL) Reactions +10 (µL) 
PreAmp Master Mix 1.00 106 
Pooled Taqman assay mix 
(0.2x)  1.25 132.5 
Water 1.50 159 
cDNA (from RT step) 1.25   
Total Volume 5.00                                397.5 
Table 8: The highlighted are the Pre-Mix. 3.75 µL was added into each well. 
 
2.4.5.4 Thermal Cycling 
 
After centrifugation the plate was placed in the thermal cycler using the following 
steps as indicated Table 9. After cycling (PreAmp) 20 µL of 1xTE Buffer (10 mM 
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Tris- HCI, 1.0 mM EDTA, TEKnova, PN T0224) was added into each well of the 
96 plate; and 2 mL of 1xTE solution was prepared per plate. 
 
Condition Hold Cycle (14 cycles)   Hold 
   Denaturation    
    Annealing/Extension     
Temperature 95oC 95oC 60oC 4oC 
       
Time 2 min 15 S 4 min ͚͚͚͚͚͚͚͚͚
 
Table 9: Thermal cycler steps, total time period is 1 hr 30 min excluding hold 
At this stage weak signals of cDNA are converted into strong signal that enables 
gene present to be detected. 
 
2.4.5.5 Preparing 10X Assays 
Aliquots of the 10X assays were prepared using the volumes in the table below 
in a DNA-free hood. All assay and sample solutions were vortexed thoroughly 
and centrifuged at 500 g for 1 min. 
 
Component Volume per 
Volume per 
Inlet 
Volume 
per 
  Inlet (μL) 
with Overage 
(μL) 
50 μL 
Stock 
20X TaqMan Gene Expression 2.5 3.0 25 
Assay (Applied Biosystems)     
      
2X Assay Loading Reagent 2.5 3.0 25 
(Fluidigm, PN     
85000736)     
      
Total Volume 5.0 6.0 50 
      
Final Concentration at 10X  Primers: 9 µM    Probe: 2.5 µL 
Table 10:  Aliquots of 10X assays, 5 µL was loaded on the chip 
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2.4.5.6 Preparing Sample Pre-Mix and Samples 
 
A sample pre-mix solution was prepared containing the master mix and 20X 
gene expression (GE) sample loading reagent as shown in Table 11. The two 
sample pre-mix components in a 1.5 mL sterile tube were combined. The 
sample pre-mix (3.3 µL) was aliquoted for each sample. The aliquots were 
removed from the DNA-free hood and 2.7 μL of cDNA was added to each 
aliquot to make a total volume of 6 μL. 
 
Component Volume Volume per Sample Pre-Mix 
  per Inlet Inlet with for 96.96 (μL) 
  (μL) Overage (μL) (120 for ease of 
      pipetting) 
2X Master mix  2.50 3.0 360.0 
      
20X GE 
Sample 0.25 0.3 36.0 
Loading Reagent    
(Fluidigm,     
PN 85000735,     
85000746)     
      
cDNA 2.25 2.7   
      
Total 5.00 6.0   
Table 11: Sample pre-mix 
 
2.4.5.7 Priming and Loading the Dynamic Array integrated fluidics circuit 
(IFC) 
 
For instructions on priming and loading the 96.96 Dynamic Array IFC, see the 
Fluidigm 96.96 Real-Time PCR Workflow Quick Reference (PN 68000130).  
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Before the assays and samples were loaded on the chip, the included syringes 
were used to inject 150 µL of the control line fluid into each accumulator on the 
96.96 chip (Figure 11). The protective film from the bottom of the chip was 
removed and discarded. The 96 chip was placed into the IFC Controller HX and 
the Prime script (136x) was run for 20 min.  
 
Figure 11 Taqman 96.96 chip 
 
Fig11: The 96.96 chip, 96 assays by 96 samples gives 9216 reaction in 6 µL chambers.  
 
2.4.5.8 Assay and Sample Loading  
 
After the chip was primed, the assays as prepared above were loaded into the 
inlets and the samples as prepared above were loaded into the sample inlets. 
Pipetting was carefully carried out to prevent air bubbles. In each inlet 
(respective inlets) 5 μL of each assay or 5 μL of each sample was added. After 
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the chip was transfer to the loader, which pushes the inputs through the 
microfluidics and mixed each sample with each assay.  The loader script (136x) 
was run for 1 hr 30min. The chip was then placed in the BioMark HD System; 
GE 96x96 standard v1.pcl was run for 3 hr. The data was collected on the 
BioMark HD System (Figure 13). 
 
2.4.5.9 Using the Data Collection Software 
 
The GE 96X96 standard v1.pcl in the GE folder was selected. The total program 
ran approximately 3 hr. The completed program is as follows see Figure 13. 
Figure 12: The cycling protocol for the 96.96 Dynamic Array IFC provided by Dr Claire Taylor 
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96.96 chip date representative 
 
Figure 13: Representative of the Taqman chip data (shown with permission from Dr Claire 
Taylor). 
 Fig A shows cycle 1 when there is no signalling or the signalling is very low. Fig B shows cycle 
40 when signalling is high, the genes present can easily be detected. Fig C and D shows the 
excitation of the signals. Fig E shows strong signals at the top (yellow) and weak or no signal 
at the bottom (black). On the right side of Fig E shows the RNA present.  
 
Gene probe selection and gene expression 
 
In our group 10 genes were selected from each IFN-annotated module (M1.2, 
M3.4, M5.12) (Chiche et al., 2014), with additional common ISGs (IFI27, IFI6). 
The selected genes were validated by meta-analysis of multiple GEO data 
biosets comparing PBMCs from SLE versus HC on Nextbio web engine. 
Peptidylprolyl isomerase A (PPIA) was used as a reference gene (confirmed 
not to respond to IFN-I). The housekeeping gene (PPIA) is considered to be the 
most stable and it is not fluctuated by IFN or IFN mediated disease compared 
to other reference genes such as, hypoxanthine-guanine 
phosphoribosyltransferase (HPRT1) and beta-glucuronidase (GUSB). 
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2.4.6 Flow method assessment  
 
Representative scatter plots for staining  
 
Figure 14: Representative scatter plots of whole blood and PBMC staining.  
Cells were stained as described in 2.4.1 for whole blood staining and 2.4.2 for PBMC staining. 
The cells were surface stained and fixed. Tetherin expression was examined using blood 
samples cells with monoclonal antibody and analysed by flow cytometry.  The intensity level of 
tetherin protein (CD317) expression was measured in each of these cell types by using the % 
parent, mean and median fluorescence intensity. 
 
 Lymphocytes, monocytes and neutrophils were gated from the forward side 
scatter (FSC) and side scatter (SSC) as shown in fig A. From the lymphocyte 
population CD3+ T-Cells, NK-cells were identified (see B). From CD3+ T-cells 
the sub population of T-Cells were differentiated as shown in fig D. CD19+ B-
Cells (fig C) were taken from the double negative population CD3-CD56- in fig 
B. CD19+ expression was further differentiated to naïve b-cell (CD27-CD38-), 
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memory b-cell (CD27+CD38-), transitional cells (CD38+CD27-) and 
plasmablasts (CD27+CD38hi) (fig E). The gates were adjusted for each sample. 
Isotypes were used as a control to adjust the tested samples.  Each sample had 
an unstained, an isotype and a test tube. Fig H shows the population hierarchy 
of the cell types and fig I show the statistical review.  
 
Definition of the cell types 
Cell types 
CD19+ 
 
B-cells 
 
CD38hiCD27- CD19+ Transitional cells 
  
CD38+CD27- CD19+ Naïve 
  
CD38-CD27+ CD19+ Memory 
  
CD28+CD27+ CD19+ Plasmablasts 
  
CD56+CD3- NK cells 
  
CD56+CD3+ NKT cells 
  
CD56-CD3- CD19 cells by exclusion 
  
CD3+CD8+CD4+ T-cells 
  
CD3+CD8+CD4- Cytotoxic T-cells 
  
CD3+CD8-CD4+ 
 
CD3+CD8-CD4- 
 
Helper T-cells 
 
CD3+ T-cells 
 
CD3+ CD3+T-cells 
Table 12: Cell types 
Lymphocytes, monocytes and polymorphs are defined by forward scatter and 
side scatter. The above cells are defined by the antibody used. NK cells (Natural 
killer cells) NKT cells (Natural killer T cells). 
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2.4.7 British Isles Lupus Activity Group (BILAG) index  
BILAG is a scoring system to evaluate the activity of lupus in clinical studies. It 
is valid, reliable and sensitive to change. BILAG is an organ-specific 86-
question assessment that incorporates an evaluation of the change in patients’ 
symptoms over the last month, combined with recent laboratory tests.  The 
overall scores were calculated for each organ system (general, 
mucocutaneous, neurological, musculoskeletal, cardiorespiratory, vasculitis, 
renal and haematological) that relates to the activity of the disease.  The 
resulting scores for each organ were stated as A through E, where A is very 
active disease, B is moderate activity, C is mild stable disease, D is resolved 
activity, and E indicates the organ was never involved. The BILAG index scoring 
is based upon the physician's intention to treat. 
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2.4.8 Data analysis 
 
The BILAG index was used to determine the patients’ disease activity. 
Descriptive statistics (mean and standard deviation, median and interquartile 
range) were used to measure the level of tetherin. Box and Whisker plots with 
5-95 percentiles were used to demonstrate the distribution of tetherin among 
the groups. Statistical analysis was performed using SPSS statistics version 24 
(IMB SPSS) and Graphpad Prism 7. All continuous variables were expressed 
as mean ± standard deviation unless stated otherwise. All continuous variables 
were compared across the groups using non-parametric test Kruskal-Wallis 
test. Dunn's multiple comparisons test was used to compare healthy control and 
remission and healthy control and flare. Differences in expression levels 
between patient groups (flare and remission) were investigated with non-
parametric Mann-Whitney U tests. Cox regression analysis was used to 
determine whether patients in remission group with higher intensity of tetherin 
can predict flare on memory B cells and monocytes. Model fit was analysed by 
omnibus tests of model coefficients. Results were indicated as the hazard ratio 
(HR) with 95% confidence interval (95% CI). P value of less than 0.05 was 
considered significant.  
ROC curve was used to determine sensitivity and specificity of the diagnostic 
value of tetherin on memory B cells of healthy control and patients (Remission 
and Flare). Score A was calculated as the median of delta CT (∆CT) of the IFN 
stimulated genes, performed by gene expression (TaqMan). 
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3.0 Results  
 
The expression level of tetherin (CD317) was determined in human blood using 
flow cytometry and gene expression (Taqman 96.96 chip method). Initial 
experiments compared peripheral blood mononuclear cells (PBMCs) staining 
with whole blood staining to determine the most effective in measuring tetherin 
levels. After the staining method was determined, healthy control, remission and 
flare groups were compared to determine the difference in tetherin levels 
between these groups. Flow cytometry measured the intensity of tetherin 
protein on blood cell surface using median MFI. Repeated measures Kruskal-
Wallis test was used to compare the degree of significant difference between 
whole blood and PBMCs staining techniques and between healthy controls, 
remission and flare groups. 
Gene expression by Taqman was analysed to detect IFN stimulated genes 
(ISGs) levels. A List of ISGs were selected to span over three annotated 
modules (M1.2, M3.4, and M5.12) (Chiche et al., 2014). The factor analysis; a 
special statistical analysis was carried out to reduce the number of variables 
(genes) into a continue score/s to categorise genes that behaved similarly. IFN-
Score A (factor A) was identified as the best group of genes that distinguished 
SLE patients from healthy controls and rheumatoid arthritis patients. These 
genes were derived mainly from M1.2 gene module (Chiche et al., 2014). IFN-
Score A was calculated as the median of ∆Ct (delta cycle threshold) of the 
correspondent genes. PPIA was the housekeeping gene used for the gene 
expression method. PPIA was used as a reference gene to calculate IFN-Score 
A ∆Ct of the corresponded ISGs.  
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3.1 Development of a whole blood assay for 
tetherin. 
The results in this section test the following hypothesis:  
Hypothesis 1: Cell specific tetherin can be measured accurately using a whole 
blood assay in a routine diagnostic laboratory. 
 
 Section methods  
 
Venous samples were obtained from 16 SLE patients using EDTA vacutainer 
tubes. Whole blood staining required 4 mL blood, whereas PBMC isolation 
required 18 mL. Cells were stained as described in 2.4.1 for whole blood 
staining and as described in 2.4.2 for PBMC staining. 
For both techniques, the level of tetherin was measured by the proportion of 
positively stained cells as a percentage of the parent gate (% parent) as well 
the median intensity of tetherin expression. The Kruskal-Wallis test was used 
to compare the expression of tetherin on the cell types for % parent and median 
fluorescence intensity (MFI) (Figure 15). Since the data was nonparametric and 
measured on a continuous scale. The cells that showed differences with the 
expression of tetherin between the staining techniques were compared using 
Wilcoxon matched-paired Signed rank test (Figure 16).  
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Section Results  
 
Comparisons of PBMCs and whole blood staining technique 
 
 
 
 
Figure 15: Representative bar charts of PBMCs and whole blood staining.  
Cells were stained as described above for whole blood and PBMC staining and assessed using 
flow cytometry. The cellular subsets are listed on the x-axis including Trans (Transitional cells). 
Figure A-B represents the % parent with positive tetherin protein expression; Figure C-D 
represents the median fluorescence intensity (MFI) of tetherin on the cell surface. Figure A and 
B graphs were drawn with mean and standard deviation, whereas Figure C and D bars shown 
the median and interquartile range. 
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The intensity level of tetherin protein (CD317) was measured in each cell type 
by using the % parent (proportion of positive cells from the parent gate, (Figure 
15A and B) and median MFI (Figure 15C and D). There were significant 
differences between the 15 cell types (P-value <0.0001). However there is no 
significant difference seen between the staining techniques (except for 
polymorphs as expected) as polymorphs were excluded from isolated PBMCs 
Figure 16).  
 
Figure 15A-B (% expression of tetherin) show there is a high percentage 
expression of tetherin protein on the cell surface of T-cells (CD3+), cytotoxic T-
cells (CD3+CD8+), helper T-cells (CD3+CD4+), naïve B cells, memory B cells 
and polymorphs. A high median intensity of tetherin protein was demonstrated 
on the cell surface of NK cells (CD56+CD3-), plasmablasts, memory B and 
monocytes (Figure 15B-C). There was a significant difference between the 
medians of 15 cell types (the corresponded cell types are defined in Table 12). 
The data shows that regardless of the methodology used, a similar proportion 
of cells stained positive for tetherin, with PBMCs staining expressed slightly 
higher intensity of tetherin compared to whole blood staining.  
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3.1.1 Comparison between PBMCs and Whole Blood staining on % 
parent and median MFI 
 
 
 
Figure 16: Comparison between PBMCs and Whole Blood staining on % parent and MFI. 
The figure shows the cells that show differences with the level of tetherin protein on  
 
Figure 15 with a P-value of <0.0001. The figures were drawn with symbols and lines. Wilcoxon 
matched-paired Signed rank test was used to assess the P-value and there is no statistically 
significant difference, except on monocytes measured with the MFI (Figure B2). However, 
tetherin is significantly more expressed with PBMC staining than whole blood staining. 
 
Figure 16 compares the three cell types that had demonstrated differences in 
the level of tetherin protein expression between the staining techniques as 
previously shown in Figure 15.  
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The Wilcoxon matched-paired Signed rank test was used to compare the 
staining techniques in Figure 16; and no statistically significant differences were 
observed except on monocytes (Figure 16B2, P-value of 0.0063). Monocyte 
within PBMCs staining is statistically more significant in comparisons to whole 
blood staining. The Spearman outcome justifies the pairing were not 
significantly effective except on monocytes (Figure 16A2) with a Spearman of 
0.5559. The above Figures (Figure 15 and Figure 16) show there is no 
significant differences in the expression level of tetherin with PBMCs compared 
to whole blood staining. The data shows that irrespective of the methodology 
used, a similar proportion of cells stained positive for tetherin. However the 
intensity of tetherin expression was slightly higher with PBMCs compared to 
whole blood lysis staining.  
There is no statistical difference observed on memory B cells which is the 
focused (investigated) cell in this study; because our previous cross-sectional 
study (discovery cohort) found memory B cell tetherin had positive correlation 
with SLE disease activity (El-Sherbiny et al., 2015). Considering the costs of 
isolating PBMCs (purchasing Leucosep Barrier Ficoll Tubes), skills involved and 
time taken to process the samples, it was decided to proceed with whole blood 
staining technique for this study.  
After determining the staining technique, whole blood staining was performed 
on remission patients, flare patients and healthy controls (healthy patients).  
 
The figure below show a comparison of tetherin protein expression on memory 
B cells with PBMCs and whole blood staining techniques. 
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Figure 17: Comparison of tetherin expression on memory B cells with PBMCs and whole blood 
staining techniques. 
The histograms are representative of tetherin protein intensity on memory B cells. Figure 17A 
represents PBMCs staining and B represent whole blood staining. The above analysis showed 
no statistically significant difference between the two staining techniques as mentioned above 
and the histograms (Figure 17) confirmed this finding.  
 
Section Conclusion 
 
It was concluded that tetherin could be measured using a whole blood assay 
under routine sample collection procedures with results of comparable accuracy 
to the discovery study performed in a university research laboratory with 
PBMCs.  Furthermore, the results showed that tetherin has a continuous, 
skewed distribution so the median MFI for each patient group and non-
parametric statistics in the subsequent analyses would be use. Monocytes had 
the highest expression of tetherin compared to memory B cells. However, 
previous work showed that memory B cell tetherin had the best correlation with 
disease activity. Therefore, tetherin level was measured on these two subsets 
for subsequent analyses (as well as a IFN score ((score A) as a comparator 
biomarker).  
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4.0 Comparing tetherin level between patient 
groups. 
The results in this section test the following hypothesis:  
Hypothesis 2: Tetherin will differentiate SLE from healthy control. 
 
Section methods  
 
Samples were obtained from 66 SLE patients in remission, 65 flaring SLE 
patients and 20 healthy controls. Whole blood flow cytometry for tetherin MFI 
was performed on each sample as described in 2.4.1. Using the same samples, 
gene expression was performed as described in 2.4.5 and IFN stimulated genes 
were used to calculate IFN-score A. 
The Kruskal-Wallis test was used to compare the groups. The Dunn’s post hoc 
for multiple comparisons test was used to compare healthy control with 
remission and healthy control with flare. The Dunn’s post hoc for multiple 
comparisons test was used to distinguish which group differed.  Mann-Whitney 
U test was used to compare flare and remission within the groups. 
Gene expression (TaqMan) method (IFN score A) was compared with flow 
cytometry to measure tetherin.   
Receiver operator curve (ROC) analysis was used to select the optimum 
sensitivity and specificity of the assay. 
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Figure 18: Representative bar charts of whole blood staining on patient groups (Remission 
n=66, Flare n=65 and healthy control n=20).  
Cells were stained as described in 2.4.1. The cells were surface stained, fixed and assessed 
by using flow cytometry. The cellular subsets are listed on the x-axis including Trans 
(Transitional cells). Figure A-C represents the median fluorescence intensity of tetherin protein 
on the cell surface. The bars show the median and interquartile range. The Kruskal-Wallis test 
was used to compare the groups.  
 
The intensity level of tetherin protein was measured in each of these cell types 
by using the median fluorescence intensity (Figure 18). The patient groups 
(remission and flare) expressed higher level of tetherin compared to the healthy 
control group. There was higher intensity of tetherin protein on the cell surface 
of NK cells, plasmablasts, memory B and monocytes, with a P-valve < 0.0001. 
The data showed that the remission group expressed highest intensity of 
tetherin compared to flare and healthy control groups. The cell types that 
showed highest median intensity of tetherin protein with statistically significant 
differences were then presented on box plots, as shown in Figure 19.  
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4.1 Comparison of level of tetherin on healthy control, remission and 
flare patients of the median intensity.  
 
 
 
Figure 19: Determining the significance difference between flow cytometry and gene expression 
of tetherin expression on memory B cells. 
Figures A-B shows the cells from Figure 18. Figures A and C show a comparison of tetherin 
protein expression based on tetherin and IFN score A. The tetherin reference range was 
determined by taking the upper confidence interval (CI = 2300) on memory B cells of the healthy 
controls. The IFN score A, reference range was determined by taking the lower bound limit 
(5.677632) of the healthy control IFN genes expression. The orange lines indicate the reference 
ranges. Box and Whisker plots are drawn with 5-95 percentiles. The darker shapes are outliers 
and were observed in all of the groups. The groups were compared using Kruskal-Wallis test. 
Dunn’s post hoc for multiple comparisons test are used to compare healthy control with 
remission and healthy control with flare. Mann-Whitney U test was used to compare flare and 
remission groups.  
 
 
Figure 19 shows there is statistically significant difference when comparing 
healthy controls against flare and remission groups. The healthy control group 
expressed the lowest level of tetherin compared to the patients groups. The 
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remission group in Figure 19A had greater median value (2770) compare to 
flare (2443) and healthy control group (2076). In Figure 19A there is a 
statistically significant difference between healthy control and remission with a 
P-value of 0.0002. When healthy control and flare groups are compared, there 
is no statistical difference with a mean rank difference -26.23 and a P-value of 
0.0380 (according to the Dunn’s post hoc for multiple comparisons test) 0.03 
(see 8.0 statistical analyses).  
Figure 19A-B shows that patients in remission group expressed slightly higher 
intensity of tetherin compared to the flare group and a statistical difference was 
shown (Figure 19A).  
 
 
Figure 19B (monocytes) shows there is statistical difference between the three 
groups with a P-value 0.0008. When healthy control and remission groups are 
compared they give a mean rank difference of -41.5 and a P-value 0.0004. 
There is a statistical difference between the groups. The healthy control group 
is statistically less significant in comparison to the remission group. When 
healthy control and flare groups are compared; there is a statistical difference 
with a mean rank difference -27.44 and a P-value 0.0283. The healthy control 
group had the lowest median value (4449) compared to the patients groups, 
flare (5898) and remission (64114) in expressing tetherin. Mann-Whitney U test 
was used to compare Flare and Remission groups. There is no statistical 
difference with a P-value 0.0698. 
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Figure 19C (score A (measured IFN stimulated genes)) shows there is a 
statistically significant difference when comparing the healthy control against 
flare and remission groups (P-value of <0.0001). There is statistically more 
significant difference between healthy control and flare group with a mean rank 
difference of 57.95 and a P-value <0.0001 and between remission and flare 
group with a P-value of <0.0001 compare to Figure 19A.  Figure 19A (memory 
B based on tetherin) shows patients in the remission group expressed higher 
intensity of tetherin compared to the flare group. However, the opposite is 
observed in Figure 19C and it shows greater statistical differences in 
comparison to Figure 19A. In Figure 19A, tetherin expression equal to or greater 
than the upper CI (2300) indicated higher expression of tetherin on memory B 
cells by flow cytometry. However, in Figure 19C score A equal to or lower than 
the lower bound limit (5.67732) indicates higher expression of score A (IFN 
gene signatures) by gene expression. The flare group had the highest median 
value (3.477) compared to the remission (5.386) and healthy control groups 
(6.02) in expressing tetherin protein.  IFN score A (gene expression method) is 
statistically more significant in comparison to tetherin expression using flow 
cytometry. The above analyses also shows that overall, SLE patients have 
higher level of tetherin compared to the healthy control group.  
 
The genes selected for IFN score A factorial analysis were ISG15, IFI44, IFI27, 
CXCL10, RSAD2, IFIT1, IFI44L, CCL8, XAF1, GBP1, IRF7 and CEACAM1. 
Score A was calculated as a median of the above genes ∆Ct. PPIA was used 
as the reference gene (housekeeping gene). 
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4.2 Sensitivity and specificity of memory B cell tetherin for diagnosis of 
SLE 
Figure 20 below shows how sensitivity and specificity of the diagnostic value of 
tetherin of healthy control and patients was determined from median intensity 
of tetherin protein on memory B cells (Figure 20A1-A2) in comparison to gene 
expression (IFN-score A) (Figure 20B1-B2).  The ROC Curve was used to 
assess the P-values, sensitivity and specificity values. 
 
 
Figure 20: Determining sensitivity and specificity of the diagnostic value of tetherin and score A  
of healthy control and patients (including Flare and Remission). 
Figures A1 and B1 graphs were drawn with mean and standard deviation. Individual values for 
each patient are shown along with mean errors bars that represent standard error mean (SEM). 
Figures A2 and B2 graphs were used to determine the sensitivity and specificity of the assays. 
It was also used to assess the area under the curve and the P-value. The orange line was drawn 
to indicate the diagnostic values predicted by the ROC Curve. 
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Figure 20A1-A2, the patients group (n=131) have greater tested values 
compared to healthy control group (n=20) and Figure 20B1-B2 patients group 
(n=82) and healthy control group (n=50). The Figure shows the healthy control 
group values are closer in range compared to the patient groups.  
 
Figure 20A2 has an area under the curve of 0.7303, P-value 0.0009, standard 
deviation error 0.04893 and 95% confident interval 0.6344 to 0.8263. For >2288 
median intensity of tetherin gives 65.65 % sensitivity and 70% specificity with a 
likelihood ratio of 2.188. Figure 20B2 has an area under the curve of 0.8009, P-
value <0.0001, standard deviation error 0.03749 and 95% confident interval 
0.7274 to 0.8743. For <5.124 IFN score A, gives 69.51% sensitivity and 80% 
specificity with a likelihood ratio of 3.476. Gene expression method (IFN score 
A) gives a greater specificity and it statistically more significant compared to 
flow cytometry tetherin measurement. 
 
The area under a ROC curve provides the overall ability of the test to 
discriminate between those individuals with the disease and those without the 
disease. A poor test has an area of 0.5 and a perfect test has an area of 1.0. 
Looking at the area under the curves and the P-values from Figure 20 we could 
conclude by stating the test does discriminate between abnormal patients and 
normal controls even though it is not a perfect test. The assay did not produce 
higher sensitivity or higher specificity when discriminating between clinically 
normal and clinically abnormal laboratory values. The values of sensitivity and 
specificity would have been great if they were close to 100%. However, our 
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assay and propose biomarker (tetherin) seems to be better in comparison to 
current C3 and C4 assays (Heidenreich et al., 2009). 
 
Section Conclusion 
From these results tetherin is significantly higher in patients with SLE, as 
expected. The sensitivity and specificity of tetherin appeared lower than 
expected. However, the SLE patient samples were obtained from patients with 
established disease.  These patients may have received glucocorticoids, 
immunosuppressants or rituximab, which may have affected tetherin levels. A 
diagnostic test for SLE is more likely to be applied to patients who are therapy-
naïve at the time of testing. This question could be explored further by testing 
the effects of therapies on tetherin levels as well as recruiting a cohort of newly 
diagnosed SLE patients. Another unexpected finding in this analysis was that 
tetherin levels were not higher in patients with flares. This contradicts the results 
in the discovery cohort. The most obvious difference between this study results 
and those in the discovery cohort is that the treating physician’s opinion of flare 
was used rather than BILAG-determined flare. Patients presenting with features 
such as joint pain without swelling might be judged by their physician to have a 
flare but do not have confirmed clinical disease activity that would score on 
BILAG. The results in the next section were analysed according to BILAG 
disease activity and indeed show a relationship between tetherin levels and 
flare. This discrepancy emphasises the importance of accurate clinical 
assessment to optimise the treatment of SLE as well as biomarkers. 
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5.0 Determining whether memory B cell tetherin 
predicts flare in patient in remission. 
The results in this section test the following hypothesis: 
Hypothesis 3: SLE patients in remission with higher level of tetherin on 
memory B cells have a significantly higher risk of flare compare to patients in 
remission with lower or normal level of tetherin. 
 
Section methods  
 
Cells were processed and stained as described in 2.4.1 and flow cytometry 
panel was performed on each sample. 
 
The level of tetherin was measured by median fluorescence intensity of tetherin 
protein. Patients with higher expression of tetherin protein from remission group 
were selected. Cox Regression and Cox regression with a time-dependent 
covariate were used to determine the degree of significant difference between 
the groups. The groups were determined whether flare (Y) or no flare (N). 
The table below (Table 13 ) outlined the 36 SLE remission patients that were 
selected for the prediction of flare, including their disease characteristics, 
demographic and their treatments. These patients expressed higher level of 
tetherin compared to the rest of SLE remission patients’ samples processed. 
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Patient Age Gender Demographic 
Disease 
characteristics 
(BILAG) Medication / Treatment 
     Muco MSK RTX Steroid Hydro 
MMF 
MTX 
AZA 
1 52 F White British D D N N Y Y 
2 34 F White British D D N Y Y N 
3 49 F White British E D N Y Y N 
4 18 F Bangladeshi D E N N Y Y 
5 59 F Caribbean D D N N Y Y 
6 57 M White British E E N N N N 
7 37 F White British E E N N Y N 
8 39 F White British E E N N Y Y 
9 66 F Caribbean D E N N N Y 
10 46 F Pakistani D E N Y Y Y 
11 33 F Caribbean E E N N Y Y 
12 41 F White British D D N N Y Y 
13 45 F Indian C C N N Y Y 
14 32 F Indian E E N N Y N 
15 74 F White British D D N Y Y Y 
16 36 F White British D D N Y Y Y 
17 66 F Mixed race D E N N Y N 
18 19 F White British D E N N Y N 
19 36 M Black African E E N N N Y 
20 63 F Indian D D N Y N N 
21 33 F Indian D C N N Y Y 
22 63 F White British D D N Y N N 
23 73 F White British D D N Y Y Y 
24 27 F White British E E N Y N N 
25 31 F White British D E N N Y N 
26 60 F White British D D N Y N Y 
27 67 F White British      C B N Y N N 
28 37 F White British D D N Y Y N 
29 63 F White British E D N N Y N 
30 29 F Caribbean D D N N Y Y 
31 46 F White British D D N N Y Y 
32 46 F Chinese D D N N Y Y 
33 47 F Chinese D D N N Y Y 
34 28 F Indian D D N Y Y N 
35 51 M Black African D C N N Y Y 
36  56 M White British D D N Y Y N 
Table 13: SLE remission patients selected for the prediction of flare. 
Majority of these patients are female within the child bearing age. Muco = 
Mucocutaneous (the involvement of skin and mucosal), MSK = 
musculoskeletal, RTX = Rituximab, Hydro = Hydroxychloroquine, MMF = 
Mycophenolate mofetil, MTX = Methotrexate and AZA = Azathioprine. N = No 
and Y = Yes. 
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Section Results  
 
The diagram below (Figure 21) shows memory B and monocytes cells with 
higher median intensity of tetherin protein. These cell types were compared to 
determine which is most likely to predict flare in SLE patients especially for 
those in remission. 
 
 
Figure 21: Determining the prediction of flare in SLE patients 
Figures A-B shows memory B cells and monocytes with higher median fluorescence intensity 
of tetherin protein. These are presented in Box and Whisker plots with 5-95 percentiles. The 
proportions were compared by chi-square. Cox Regression and Cox regression with a time-
dependent covariate were used to determine the degree of significant difference. The groups 
were determined whether flare (Y) or no flare (N) 0.00= No Flare (n=28) and 1.00= Flare (n=8) 
(Y=yes and N=no). 
 
Figure 21A (memory B cells) shows there is a significant difference between the 
two groups in the expression of tetherin protein on memory B cell surface. The 
flare group is statistically more significant compared to the remission group. The 
flare group have a smaller number of patients (n=8) compared to the remission 
group (n=28) but shows higher intensity of tetherin on memory B compared to 
the remission group. The Cox Regression gives a Chi-square of 5.623 and a P-
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value 0.018 overall score. There is a statistical difference between these groups 
(Table 14) and Table 15 confirms the statistical difference. This shows that 
memory B is a better predictor of flare compared to monocytes. 
Figure 21B (monocytes) shows the remission group demonstrates similar 
distribution of the intensity of tetherin protein compared to the flare group.  The 
flare group expressed slightly higher intensity of tetherin compared to the 
remission group; however, there is no statistical difference. Cox Regression 
gives a Chi-square of 0.580 and no statistical difference with a P-value 0.446 
for the overall score (Table 14). 
 
The tables below showed the significant differences of both cells type. 
Cells Type 
- 2 Log 
Likelihood 
Overall (score) Change From Previous Step 
Chi-square df Sig. Chi-square df Sig. 
                
Monocytes 51.625 0.580 1 0.446 0.535 1 0.465 
                
Memory B 47.828 5.623 1 0.018 4.332 1 0.037 
                
Change From Previous Block 
Chi-square df Sig 
      
0.535 1 0.465 
      
4.332 1 0.037 
      
Table 14: Omnibus Tests of Modal Coefficients. 
The Omnibus Tests of Modal Coefficients generated -2 Log Likelihood 52.160. 
From Table 14, monocytes have an omnibus tests of modal coefficient (51.625) 
close to 52.160 compared to the Memory B (46.377). The P-values shows that 
memory B is statistically more significant in predicting flare compared to 
monocyte.  
  
Page 98 
 
  
  B SE Wald df Sig. 
EXP 
(B) 
95% Cl for Exp 
(B) Covariate 
              Lower Upper Mean 
Monocytes                   
Tetherin 
1000s 0.077 0.101 0.578 1 0.447 1.080 0.886 1.316 6.402 
                    
Memory B                   
Tetherin 
1000s 0.5 0.225 4.949 1 0.026 1.649 1.061 2.562 2.605 
Table 15: Variables in the equation 
The above table shows memory B is statistiscally significant in predicting flare 
compared to monocytes. Memory B cells have a lower P-value, a higher 
hazared ratio (Exp (B)) and a lower convariate mean compared to monocytes. 
Because the hazard ratio for memory B was above 1 and confidence interval 
(95% for Exp (B)) is above 1.0, these findings indicate that having high level of 
tetherin protein on memory B cells increases the risk of flare. This is because it 
increases the risk of the flare with a higher hazard ratio and higher confidence 
interval (95% for Exp (B)) compared to monocytes.  
 
 
Section conclusion 
 
These results confirmed the hypothesis that, when patients are in clinical 
remission, the presence of high memory B cell tetherin predicts a higher rate of 
clinical flare in follow up. This is clinically useful, as when patients are in 
remission physicians may want to reduce therapies such as glucocorticoids if 
the risk of flare is low. However, they may even want to increase therapy (or 
repeat a cyclic treatment such as rituximab) if risk of flare is high. The main 
limitation of these results is that covariates were not adjusted such as other 
therapies. This would require a larger sample with more detailed clinical. 
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6.0 Determining whether tetherin level falls at 
follow up of flare patients. 
The results in this section test the following hypothesis: 
Hypothesis 4: SLE patients who are flaring will show a reduction in tetherin 
level following treatment. 
 
Section methods  
Sample was obtained from 15 SLE flaring patients according to BILAG score. 
Flow cytometry panel was performed on each sample. Cells were stained as 
described in 2.4.1 and level of tetherin was measured by median fluorescence 
intensity of tetherin protein. Tetherin intensity was measured at baseline and at 
follow up visit. Wilcoxon matched-paired Signed rank test was used to compare 
the groups. The table below gives a snap shot of the 15 patients, with their 
condition, treatments and demographic.  
Patient Age Gender Demographic 
Disease 
characteristics 
(BILAG) Medication / Treatment 
        Muco MSK RTX Steroid Hydro 
MMF 
MTX 
AZA 
1 62 F White British A B Y Y N Y 
2 40 F Indian B D Y Y Y Y 
3 48 F Black C D Y Y Y Y 
4 30 F Pakistani B B Y Y Y Y 
5 34 F White British B D Y Y N Y 
6 43 F White British B B Y N Y Y 
7 47 M Caribbean B C N Y Y Y 
8 61 F White British C D N N Y Y 
9 42 F N/A D C N N Y N 
10 34 F White British B C N Y Y Y 
11 32 F N/A D A Y Y Y Y 
12 42 F White British A B Y Y N Y 
13 69 F White British C D Y Y Y Y 
14 33 F Indian B C N Y Y Y 
15 46 F White British B C Y N Y Y 
Table 16: SLE BILAG flare patients used to determine the effect of treatments. 
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Muco = Mucocutaneous, MSK = musculoskeletal, RTX = Rituximab, Hydro = 
Hydroxychloroquine, MMF = Mycophenolate mofetil, MTX = Methotrexate and 
AZA = Azathioprine. N = No and Y = Yes. 
 
Section Results 
 
Figure 22 below, shows the median intensity of tetherin protein on memory B 
cell surface in flare patients. The median intensity of tetherin protein was 
compared between the first and second visit. This is to determine whether the 
level of tetherin decreases with treatment, and whether this was associated with 
patients going into remission. 
 
 
Figure 22: 15 repeat measures of median fluorescence intensity of memory B tetherin 
expression on Flare patients 
The Figure represents the median fluorescence intensity of tetherin protein on memory B cell 
surface on SLE flare patients. Figure B was drawn with mean and standard deviation. Wilcoxon 
matched-paired Signed rank test was used to assess the P-value and there is no significant 
difference. Figure 22B1 shows there is no significant difference between the first and second 
visit. Figure 22B2 shows there is no or poor correlation between the visits.  
  
Page 101 
 
  
Figure 22A shows there is a difference between the visits. Patient 3, 4, 5, 6, 7, 
9, 12 and 15 have higher median intensity of tetherin in the first visit compared 
to the rest of the patients. Patient 1, 8,10,11,13, and 14 have higher median 
intensity of tetherin in the second visit compared to the rest of the patients. A 
significant difference was noted from both visits with patient 1, 6, 7, 8, 9, 10 and 
14. Patient 2 shows no difference. There is a significant decrease of tetherin 
expression level noted on patients 5 and 7 on the second visit compared to the 
first visit. Patient 1, 8, 10 and 14 shows a significant increase in the level of 
tetherin in the second visit compared to the first visit. Patient 9 is shown to 
express the highest level of tetherin on both visits compared to the rest to the 
patients.  
 
Figure 22B, the intensity of tetherin protein increased slightly in the second visit 
compared to the first visit. However there is no statistically significant difference 
with the intensity of tetherin on memory B in both visits as shown by Wilcoxon 
matched-paired Signed rank test, P-value 0.9341. The statistical analysis gives 
a sum of signed ranks (W) -4 and median difference of -507. Spearman 0.2449 
outcome justifies the pairing was not significantly effective. 
 
Section Conclusions 
 
These results did not support the hypothesis, there is no change observed in 
tetherin level in follow up. Unfortunately, however, there were major limitations 
to this analysis. The number of follow up samples received was much lower 
than expected. This prevented analysis to be performed in patients who 
improved to remission in follow up. We were also unable to test whether 
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different levels of flare at baseline and different types of therapy would have 
more or less effect on change in tetherin levels. Therefore, no conclusion is 
drawn for this hypothesis, but these results would help to design a definitive 
study with larger numbers in future. 
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7.0 Use of tetherin as a biomarker to select 
targeted therapy.  
The results in this section test the following hypothesis: 
Hypothesis 5: Tetherin may have value as part of a biomarker panel to select 
patients for targeted therapy. 
 
Section methods 
 
Interferon-blocking biologic therapy (anifrolumab) is currently in phase III clinical 
trials and phase II data suggest it should only be prescribed to patients who 
have evidence of high interferon activity. Tetherin might be useful for this 
purpose. Another biologic is already licensed for SLE: the anti BAFF biologic 
belimumab. In England, belimumab is only commissioned for patients who have 
“B cell biomarkers” that have raised levels of anti-dsDNA antibodies and low 
levels of complement C3 or C4.  There was no access available to samples 
from patients treated with anifrolumab. However, tetherin results from this study 
was used to test how many patients would be judged to be eligible for each of 
these agents if both were available.  This judgement depends on the 
relationship between the tetherin and B cell biomarkers. 
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Section Results: illustration of patients that could be eligible for IFN blocking therapy.   
 
              Anifrolumab 
              Y                  N 
                          
                                  Y 
                 Belimumab 
                                  N 
 
 
 
              Anifrolumab 
             Y                  N 
                          
                                  Y 
                 Belimumab 
                                  N 
Table 17: SLE patients that would be appropriate for either anifrolumumab or belimumab or for 
both drugs and not suitable for either (Y= yes and N= no). 
 
Table 17A was created based on tetherin expression. It only includes the primary or single visit 
(n=51). Table 17B was created based on interferon (IFN) score A, only includes the primary 
score A (n=51). Tetherin reference range was determined by taking the upper confidence 
interval (CI = 2300) of memory B cells of the healthy controls.  IFN score A, reference range 
was determined by taking the lower bound limit (5.677632) of the healthy control ISGs 
expression. % was determined by the number of patients divided by ‘n’ multiple by 100.   
 
 
Valid for both drugs 
7 (13.73%) 
Belimumab only 
2 (2.92%) 
Anifrolumab only 
25 (49.02%) 
Invalid for both drugs 
17 (33.35%) 
Valid for both drugs 
9 (17.65%) 
Belimumab only 
0 (0%) 
Anifrolumab only 
31 (60.78%) 
Invalid for both drugs 
11 (21.57%) 
A: based on tetherin expression  
B: based on IFN score A 
  
Page 105 
 
  
Table 17A gives an indication of flare patients that would be eligible for either 
anifrolumab or belimumab or for both drugs. It also shows patients that were 
not eligible for either drug based on tetherin expression. The tetherin reference 
range was determined by taking the upper confidence interval (CI = 2300) of 
the intensity of tetherin expression on memory B cells in healthy controls. 
Tetherin expression above the CI value indicates high expression of tetherin.  
Table 17B gives an indication of flare patients that would be appropriate for 
either anifrolumab or belimumab or for both drugs, and patients that would not 
be suitable for either drugs based on interferon (IFN) gene expression score A. 
IFN score A, reference range was determined by taking the lower bound limit 
(5.677632) of the healthy control IFN genes expression on memory B cells. 
Score below the lower bound value (reference range) indicate high expression 
of tetherin. Majority of the patients are eligible for anifrolumab. Table 17 was 
presented on graphs format and healthy controls are included to illustrate the 
data better, see Figure 23 below. 
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Figure 23: illustration indicating SLE flare patients eligible for either IFN blocking therapy or anti-
BAFF therapy or eligible for both and not eligible for either therapy.  
Figure 23A-B shows patients that are below and above the mean. Figure 23A was created 
based on tetherin expression on memory B cells. Figure 23B was created based on IFN score 
A. The dotted line gives an indication of the reference range. Tetherin reference range was 
determined by taking the upper confidence interval (CI = 2300) of memory B cells of the healthy 
controls.  IFN score A, reference range was determined by taking the lower bound limit 
(5.677632) of the healthy control IFN genes expression. 
 
Figure 23A shows patients eligible for anifrolumab and eligible for both therapy 
expressed tetherin that is equal or greater than the upper CI value (CI=2300). 
It also showed that patients eligible for belimumab and those that were not 
eligible for both therapy expresses lower intensity of tetherin, that is below the 
upper CI value.  
 
Figure 23B shows IFN score A (lower bound limit = 5.677632) was calculated 
based on the IFN genes expression. Scores that are equal or below the 
reference score A (5.677632) expressed higher level of IFN compered to scores 
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above (5.677632). Figure 23B1-B2 shows no patients in our cohort is eligible 
for belimumab based on the IFN score A. Majority of the patients are eligible of 
anifrolumab and fewer eligible for both treatments.  
 
Section conclusion 
 
These results illustrate how a convenient interferon biomarker could be applied 
in routine clinical practice.  The results shows that the majority of flaring patients 
have evidence of increased interferon activity using tetherin, a proportion that 
is consistent with other population data using gene expression assays. For the 
first time we show the relationship between the biomarker criteria for these two 
biologic therapies. These data show that the population of patients eligible for 
anifrolumab is larger and further includes almost all the patients eligible for 
belimumab. 
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8.0 Statistical Analysis  
The Kruskal-Wallis test was used to compare the groups. This test is 
an omnibus test statistic and it cannot tell which specific groups of the 
independent variable are statistically significantly different from each other; it 
only tells at least two groups were different.  When comparing three groups 
(healthy control, flare and remission groups) determining which of these groups 
differ from each other, Dunn’s multiple comparisons test was used.  
 
Dunn's multiple comparisons test was used to determine the level of 
significance where 0.05 was divided by the number of groups compared, so 
0.05 was divided by 2 = 0.025, therefore the level of significant is 0.03. This was 
used to determine which groups differ. Dunn's multiple comparisons test are 
multiplicity adjusted P values. 
The Kruskal-Wallis test analysis indicates significant differences between the 
medians. Significant differences (P-values) were less than 0.05.  
Cox regression, the omnibus tests of modal coefficients (Chi-square) test did 
not distinguish which group differ, the variables in the equation determined 
which group differ. 
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9.0 Discussion  
 
This study investigated several aspects of tetherin as a biomarker in SLE. We 
showed several areas in which there is potential utility; tetherin functioned as a 
cell-specific interferon biomarker as expected, correlated with diagnosis and 
predicted flares. Our results also suggest how tetherin could be used in future 
to select patients for interferon-blocking therapy. Below covers the discussion 
of the positive and negative findings, limitations, and the potential for future 
work. 
Tetherin was initially discovered as a cell surface protein that was highly 
expressed on multiple myeloma cells (Wang et al., 2009). This anti-viral gene 
has also been identified as being overexpressed in many solid organ tumours, 
including breast cancer (Mahauad-Fernandez et al., 2015). It has been noted 
to be critical for the invasiveness of breast cancer cells and the formation of 
metastasis in vivo (Mahauad-Fernandez et al., 2015). Several studies have 
been carried out to determine the effect and impact of tetherin in cancer and 
HIV studies.  
In 2014 Mahauad-Fernandez et al performed a Meta-analysis of tumours from 
breast cancer patients obtained from the Gene Expression Omnibus (GEO) and 
The Cancer Genome Atlas (TCGA) data-sets and they were evaluated for levels 
of BST-2 (tetherin) expression and for tumour aggression. In humans, they 
found tetherin mRNA was elevated in metastatic and invasive breast tumours 
(Mahauad-Fernandez et al., 2014a). Their findings demonstrated that tetherin 
contributes to the emergence of neoplasia and malignant progression of breast 
cancer. The group concluded tetherin may serve as a biomarker for aggressive 
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breast cancers, and may also be a novel target for breast cancer therapeutics 
(Mahauad-Fernandez et al., 2014a). 
A comprehensive meta-analyses of BST-2 gene expression and BST-2 DNA 
methylation in TCGA and various GEO datasets (Mahauad-Fernandez et al., 
2015) was carried out to compare tetherin expression levels and tetherin DNA 
methylation status at specific CpG sites on the tetherin (BST-2) gene by 
Mahauad-Fernandez et al (2015). The findings show that tetherin gene 
expression was associated with the methylation status at specific CpG sites in 
primary breast cancer specimens and breast cancer cell lines. They found out 
that, tetherin demethylation was significantly more predominant in primary 
tumours and cancer cells than in normal breast tissues or normal epithelial cells. 
These findings suggested that DNA methylation pattern and expression of 
tetherin may play a role in disease pathogenesis and also suggested it could 
serve as a biomarker for the diagnosis of breast cancer. 
Tetherin is an interferon-inducible protein and has vital roles in anti-viral 
immunity. HIV studies have shown tetherin to impair the release of mature HIV-
1 particles from infected cells. Tetherin has been found to be an innate 
restriction factor limiting HIV cell-to-cell spread. It acts by impairing viruses in 
donor cells, and significantly reducing their infectious potential once they have 
been transferred to target cells (Casartelli et al., 2010). Other HIV studies have 
shown that tetherin is upregulated in infected patients compared to healthy 
controls. A study carried out by (Homann et al., 2011) showed the detection of 
BST-2 by flow cytometry on the surface of subsets of peripheral blood 
leukocytes, including CD4+ T-cells from healthy and HIV infected individuals. 
They found out BST-2 was upregulated by 2 to 3 fold on cells of infected patients 
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(Homann et al., 2011). It was shown the upregulation occurs on CD4+ T-cells 
and appears to be part of an innate response to the virus itself.  However, they 
later observed that elevated levels decreased slightly during chronic HIV 
infection by effective antiretroviral therapy (Homann et al., 2011). It is because 
of the interferon-inducible character of tetherin that makes it have the potential 
value as an SLE biomarker. The unique property of this protein is that most 
other interferon inducible proteins are intracellular or, in the case of sialic acid 
binding Ig-like lectin 1 (SIGLEC-1), highly expressed on monocytes (Xiong et 
al., 2017). A limitation of gene expression assays for interferon, apart from 
logistical difficulty of using gene expression in routine clinical practice, is that 
they may be affected by changes in the cellular composition of the sample 
rather than a change in secretion of the interferon ligand. Flow cytometry 
removes this problem, and also allows analysis of specific cell subsets (such as 
B cells) that have a more prominent role in models of SLE pathogenesis. 
 
9.1 Evaluation of the comparison between PBMC and Whole Blood 
staining. 
The first section addresses basic requirements for the measurement of tetherin. 
Tetherin expression was similar between PBMCs and whole blood staining. The 
findings demonstrated that the staining protocols produced similar levels of 
tetherin protein on the cell surface for most subsets. PBMC staining showed a 
slightly higher median intensity of tetherin protein compared to whole blood 
staining but this was not statistically significant except for monocytes. We 
previously found that, although tetherin MFI was high on monocytes, this did 
not correlate well with clinical characteristics of SLE. Memory B cells tetherin 
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was previously found to best correlate with clinical outcomes and was, 
therefore, the priori focus of my study. 
The use of whole blood to perform lymphocyte subsets analysis is a 
straightforward procedure compared to the laborious preparation for the 
analysis of isolated PBMC with cell enumeration (Appay et al., 2006). 
Additionally, it has the advantage to the patient of requiring only small amounts 
of blood 4 mL compared to PBMCs which requires 18 mL (Marits et al., 2014). 
The results are therefore essential if memory B cells tetherin is to be analysed 
in a routine diagnostic laboratory setting. After considering the disadvantages 
of PBMC (PBMC density gradient separation) isolated by Ficoll, it was decided 
to proceed with whole blood staining technique for this study.  
Our results also demonstrated that tetherin MFI is a better measure of 
expression than proportion of “tetherin positive” cells.  The skewed distribution 
of tetherin MFI indicates that median MFI should be reported in clinical use, and 
that non-parametric statistics should be used in research. We understand the 
difficulties of using MFI based cytometric measurement technique across 
different laboratories however; these can be minimised by using the same batch 
and clone of monoclonal antibodies. Set the voltages and perform 
compensation using cells instead of beads. Perform baseline check every 6 
months, Calibrate and run quality control (CS&T beads) daily to ensure the 
lasers are set. We could also use standardised MFI reference beads. 
Standardised MFI beads would reduce changes between different Flow 
cytometry. We believe reproducibility would be achieved through utilisation of 
standard operating procedures, common reagents and normalisation 
algorithms. 
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Flow cytometry is routinely used in other clinical settings such as HIV 
monitoring, immunodeficiencies and, in rheumatology, monitoring B cell 
numbers after anti-CD20 therapy. Most of these applications rely on 
enumerating cell populations rather than fluorescence intensity.  
 
9.2 Comparing tetherin expression between different patient groups.  
The SLE patient groups and healthy control group level of tetherin were 
compared to determine which group produced the highest level of tetherin. We 
confirmed that, as expected, the SLE patients exhibited a higher level of tetherin 
compared to the healthy controls. Surprisingly, when flare and remission 
patients were compared, remission group expressed higher level of tetherin 
compared to flare. 
Previous studies have sought to compare interferon activity using gene 
expression with disease activity.  Although some showed a correlation, others 
did not (Niewold et al., 2010, Blanco et al., 2001, Chiche et al., 2014). We had 
hypothesised that tetherin would clarify this and indeed my group’s previous 
work showed a closer correlation of memory B cells tetherin with diagnosis and 
disease activity than gene expression. Although this study did not reproduce 
that finding, there are several limitations to the study that may have affected the 
findings and would need further research to explore. First, this study was 
designed to mimic routine care and we therefore asked requesting physicians 
to label samples as either “flare” or “remission”. Assessment of disease activity 
in SLE is difficult. Physicians may decide that a patient is likely to be flaring 
based on subjective symptoms such as joint pain without objective evidence, 
and treat them accordingly. In my group’s previous research we avoided this 
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problem by using BILAG scores, which require objective evidence to score 
highly for disease activity. Second, this setting, as well as the patient numbers 
in the study, did not allow us to control other characteristics such as organ 
involvement and therapy. In our group’s previous research interferon activity 
was found to be more closely associated with certain organs (such as skin 
disease), with no association with musculoskeletal disease. 
Immunosuppressant therapies, prescribed in flare patients, modify biological 
parameters as well as clinical disease activity and may have affected my 
findings (Homann et al., 2011). The effect of rituximab may be particularly 
important since it depletes memory B cells as well as lowering the tetherin 
expression in the small numbers of repopulating B cells (Vital et al., 2011). A 
new study in Leeds (DEFINITION) has been designed to overcome these 
problems and my results were used to design that study. 
 
2.1 Evaluating the sensitivity and specificity of memory B cell tetherin 
for diagnosis of SLE using flow cytometry in comparison to gene 
expression. 
We determined the sensitivity and specificity of the diagnostic value of tetherin 
on memory B cells by comparing healthy controls and patients (both Flare and 
Remission). We found that gene expression (IFN score A) produced slightly 
higher sensitivity (69.51%) and better specificity (80%) in comparison to flow 
cytometry sensitivity (65.65 %) and specificity (70%). We concluded by stating 
the test does discriminate between abnormal patients and normal controls even 
though the assay level of sensitivity and specificity of this test in isolation of 
other clinical criteria and biomarkers is suboptimal. 
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Producing an accurate assay with high sensitivity and high specificity would aid 
in the diagnosing, stratifying and monitoring of the SLE disease. It would also 
ensure that SLE patients receive appropriate treatment promptly. However, for 
a test to be clinically useful and to be introduced into routine clinical practice, 
the assay must be sensitive enough to detect the analyte of interest (Powers 
and Palecek, 2012), in our case tetherin protein. The assay must be specific to 
the protein that it aims to detect as there is less protein concentration in blood 
and our assay produced 70% specificity. Interferon activity is a marked feature 
of SLE but is not unique to this disease, as discussed above. 
Alternative biomarkers commonly used in diagnosis of SLE are autoantibody 
tests. A study carried out by Heidenreich et al (2009) investigated the diagnostic 
value of nine kits for autoantibody against ds-DNA, ANA, circulating ICs, C1q, 
histones, nucleosomes, Sm, C3 and C4 levels. These kits were evaluated in 39 
patients with biopsy-proven lupus nephritis in comparison to 43 patients 
suffering from other forms of glomerulonephritis (Heidenreich et al., 2009). They 
only found one test to be useful which was anti-nucleosome antibody performed 
by enzyme-linked immunosorbent assay (ELISA) with a sensitivity of 90% and 
a specificity of 88% (Heidenreich et al., 2009). This study proves that our assay 
would not be a useful test in routine clinical practice as it produced less 
sensitivity and less specificity. The tests for anti-dsDNA antibodies performed 
with Crithidia luciliae Anti-dsDNA and BINDAZYME Anti-dsDNA were found to 
be of moderate sensitivity and good specificity. However, anti-C1q and ICs 
performed worse than the anti-dsDNA tests, with less sensitivity and less 
specificity (Heidenreich et al., 2009).  
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9.3 Determining whether Tetherin can predict flare in SLE patients. 
Because SLE has a relapsing-remitting disease course, prediction of flare is an 
unmet need for rheumatologists and immunologists. The level of tetherin on 
Memory B cells and monocytes were therefore investigated to identify whether 
it could predict flare, as well as which cell type would be best at predicting flare. 
We found that, although the flare group consisted of only 8 patients compared 
to the remission group (n=28), the flare group showed a significantly higher 
intensity of tetherin on Memory B cells.  In contrast, when analysing monocytes 
there was no statistical difference between the groups. These findings are of 
great interest as, not only does tetherin appear clinically useful, they also 
underline the central hypothesis that interferon response in particular cell 
subsets may be more clinically significant than others.  
 
Patient numbers were too low to create an entirely adjusted Cox regression 
model, that accounts for the other co-factors that can affect flare-free survial, 
for example medication (immunosupressants) ethnic background and age, C3, 
C4 and anti-DNA levels.  
Other studies have investigated biomarkers predictive of flare in SLE patients, 
and they have discovered that increased IFN levels correlate with disease flares 
(Landolt-Marticorena et al., 2009, Niewold et al., 2010). A cross-sectional study 
showed that IFN-induced chemokines correlated with disease activity as the 
expression increased at the time of flare, and decreased as the disease remitted 
(Landolt-Marticorena et al., 2009), suggesting that these chemokine could be 
used as a potential biomarker during the study. This is consistent with our 
finding. 
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9.4 Determining whether the Median intensity of tetherin protein on 
Memory B cells decreased in the second visit with Flare patients. 
The level of tetherin on memory B cells was measured by flow cytometry at both 
the baseline visit and a follow up visit on 15 SLE flare patients. A significant 
difference was noted between both visits for some with patients.  As all patients 
received treatment at first visit, the decrease in the expression of tetherin could 
be a positive response to treatment. However, there was no overall statistical 
difference in the intensity of tetherin protein on memory B cells at follow up, as 
we had hypothesised. 
Apart from the limited patient numbers, this could be due to varying treatments 
prescribed, types of flare, and variable response to treatment (in most trials 
clinical response rates are around 50%).  We were able to confirm objective 
flare in our 15 patients but these issues could be resolved in a larger study. 
 
9.5 Evaluating the use of tetherin as a biomarker to select targeted 
therapy. 
As there are now interferon-blocking studies in phase III trials, an interferon-
specific biomarker is likely to be of value in selecting patients for therapy. SLE 
is clinically and immunologically heterogeneous, and biomarkers may by 
valuable to stratify patients according to the most appropriate therapeutic target 
(Psarras et al., 2017). Anifrolumab (an interferon-blocking biologic) appears to 
be most useful in patients with high interferon activity. Meanwhile, the B cell 
targeted agent belimumab is most effective, and routinely commissioned, in 
patients with B cell biomarkers of activity (anti-dsDNA titres and low 
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complement). We therefore used my results to estimate how many flaring 
patients would be appropriate for one, both or neither of these therapies. 
We found that a larger number of flare patients appeared eligible for IFN 
blocking therapy rather than anti-BAFF therapy (belimumab). Almost all patients 
eligible for belimumab would also be eligible for anifrolumab. This illustrates 
how a convenient interferon biomarker could be applied in routine clinical 
practice, allowing the tailoring of medication to each individual patient.  Blocking 
the production of IFN (IFN pathway) could, in patient with high tetherin 
expression, potentially improve prognosis and consequently decrease mortality 
and morbidity. Further work would involve the use of tetherin levels in patients 
receiving anifrolumab and belimumab therapy when these are more widely 
available.  
 
In conclusion, this study has evaluated tetherin expression using two 
complementary methods, flow cytometry and gene expression using qRT-PCR. 
We have identified that tetherin expression is significantly higher in patients with 
SLE in comparison to healthy controls, with sensitivity of 65.65% and specificity 
of 70% by flow cytometry. Additionally we found that in patients with clinical 
remission, the presence of high memory B cell tetherin predicted a higher rate 
of flare in follow up. This has the potential to be clinically useful, as memory B 
cells tetherin may guide physicians in the adjustment of maintenance therapies 
based on the predictive risk of flare. Unfortunately we did not observe a change 
in tetherin level in follow up, when compared tetherin expression on memory B 
cells on baseline and follow up visits with flare patients. The number of follow 
up samples received was much lower than anticipated. We also examined how 
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convenient interferon biomarker could be applied in routine clinical practice.  We 
found that the majority of flaring patients have evidence of increased interferon 
activity using tetherin (flow cytometry), a proportion that is consistent with using 
gene expression assay.  We found out that the population of patients’ eligible 
for anifrolumab is larger than, and inclusive of, the patients eligible for 
belimumab. Tetherin has shown to have potential factors that would make it to 
be a reliable biomarker for SLE patients in comparison to the current biomarkers 
(e.g. anti-dsDNA, C4, C3). Due to the limitations experienced in this study, it 
would be useful to explore these limitations in a future study, which would help 
to generalise the findings and draw accurate conclusions. 
 
 
10.0 Proposal for future work 
 
This study aimed to create an accurate assay and to identify a reliable 
biomarker for SLE patients using limited sample sizes. In light of the findings, a 
definitive study has been designed. A sample size using 450 patients will be 
processed in a future multicentre trial with the same analytic techniques 
established. This will allow adequate power and clinical phenotyping to allow a 
final conclusion as to whether tetherin (or other interferon biomarkers) are 
valuable for the diagnosis, monitoring and treatment stratification of SLE 
patients. 
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Appendices  
 
Appendix 1 
 
Reagents  
FACSFlow solution (Becton Dickinson), FACS Shut-down solution (Becton 
Dickinson), FACS Cleaning solution (Becton Dickinson), monoclonal antibodies 
(Miltenyi Biotec), Isotype (Miltenyi Biotec), Fragment crystallisable receptor 
blocking (FC blocking) buffer (Miltenyi Biotec), lysing solution (Becton 
Dickinson), dilute to 1/10 with distilled water. 1% Phosphate-buffered saline / 
Foetal bovine serum (PBS / FBS) (wash buffer) - made with 500 mL PBS and 5 
mL of foetal bovine serum (FBS Invitrogen). 0.5% Formaldehyde (Fix solution): 
made with 1.35 mL 37% formaldehyde (BDH) and 100 mL PBS. 
 
Blocking Fc buffer: Add SIGMA 12411 - 10 MG IgG from human serum 
(reagent grade ≥ 95% (HPLC)) buffered aqueous solution into SIGMA m5905 
- 10 mL mouse serum. Aliquot 300 µl into Eppendorf tubes and freeze, when 
in need of use defrost and add 1000 µl of 1% FACS buffer containing azide 
containing. 
 
Wash buffer :1000 µL of 1% Phosphate-buffered saline / Foetal bovine serum 
(PBS / FBS) solution (wash buffer) and 49 mL of 1% PBS / FBS wash buffer 
was then added into the Falcon tube ((1% PBS / FBS - made with 500 mL PBS 
and 5 mL of foetal bovine serum (FBS Invitrogen)). 
 
Cell Fix buffer: PBS + 0.5% formaldehyde. (Fix solution, made with 1.35 mL 
37% formaldehyde (BDH) and 100 mL PBS). 
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TanMan 
Required Reagents  
• PreAmp Master Mix (Fluidigm, PN 100-5580, 100-5581)  
• 20X TaqMan Gene Expression Assays (Applied Biosystems)  
• 2X Assay Loading Reagent (Fluidigm, PN 85000736)  
• 20X GE Sample Loading Reagent (Fluidigm, PN 85000735, 85000746)  
 
Required Equipment  
• Standard 96-well Thermal Cycler  
• IFC Controller MX (for the 48.48 Dynamic Array IFC) or HX (for the 96.96 
Dynamic Array IFC) or RX (for the 192.24 Gene Expression IFC)  
• BioMark™ HD System  
 
Required Software  
Fluidigm® Real-Time PCR Analysis Software v.3.0.2 or higher and BioMark™ 
HD Data Collection Software v.3.0.2 or higher is required for this advanced 
development protocol. 
 
